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SUMMARY 
 
Marine sponges and their associated bacteria have been proven to be a rich source of 
novel secondary metabolites with therapeutic usefulness in infection and autoimmunity. 
This Ph.D. project aimed to isolate bioactive secondary metabolites from the marine 
sponges Amphimedon compressa, Aiolochroia crassa and Theonella swinhoei as well as 
from bacteria associated with different Caribbean sponges, specifically actinomycetes 
and sphingomonads. In this study, amphitoxin was isolated from the crude methanol 
extract of the sponge A. compressa and it was found to have antibacterial and anti-
parasitic activities. Amphitoxin showed protease inhibitory activity when tested against the 
mammalian protease cathepsin B and the parasitic proteases rhodesain and falcipain-2. 
Furthermore, miraziridine A was identified in the dichloromethane extract of the sponge T. 
swinhoei collected offshore Israel in the Red Sea. Miraziridine A, a natural peptide 
isolated previously from the marine sponge Theonella aff. mirabilis, is a potent cathepsin 
B inhibitor with an IC50 value of 1.4 g/mL (2.1 M).  
 
Secondary metabolites from sponge-derived bacteria were also isolated and identified. A 
total of 79 strains belonging to 20 genera of the order Actinomycetales and seven strains 
belonging to two genera of the order Sphingomonadales were cultivated from 18 different 
Caribbean sponges and identified by 16S rRNA gene sequencing. Seven of these strains 
are likely to represent novel species. Crude extracts from selected strains were found to 
exhibit protease inhibition against cathepsins B and L, rhodesain, and falcipain-2 as well 
as immunomodulatory activities such as induction of cytokine release by human 
peripheral blood mononuclear cells. The isolates Sphingobium sp. CO105 and 
Lapillicoccus sp. BA53 were selected for cultivation, extraction and purification of 
bioactive metabolites based on initial bioactive screening results. The isoalloxazine 
isolumichrome was isolated from the strain Sphingobium sp. CO105 which inhibited the 
protease rhodesain with an IC50 of 0.2 M. The strain Lapillicoccus sp. BA53 was found to 
produce p-aminosalicylic acid methyl ester, which showed activity against the proteases 
cathepsins B and L, falcipain-2 and rhodesain. These results highlight the significance of 
marine sponge-associated bacteria to produce bioactive secondary metabolites with 
therapeutic potential in the treatment of infectious diseases and disorders of the immune 
system. 
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ZUSAMMENFASSUNG 
 
Marine Schwämme und damit assoziierte Bakterien stellen eine wertvolle Quelle für 
neuartige Sekundärmetabolite mit therapeutischer Bedeutung für Infektion und 
Autoimmunität dar. Ziel dieser Doktorarbeit war die Isolierung bioaktiver 
Sekundärmetabolite aus den marinen Schwämmen Amphimedon compressa, Ailochroia 
crassa und Theonella swinhoei sowie von Bakterien, die mit verschiedenen karibischen 
Schwämmen assoziiert sind, wie z. B. Actinomyceten und Sphingomonaden. Amphotoxin 
wurde in dieser Studie aus dem methanolhaltigen Rohextrakt des Schwammes A. 
compressa isoliert. Es konnte sowohl eine antibakterielle als auch antiparasitäre Aktivität 
nachgewiesen werden. Der Einfluss von Amphotoxin auf die humane Protease Cathepsin 
B und die parasitären Proteasen Rhodesain und Falcipain-2 wurde ebenfalls getestet und 
es zeigte sich eine inhibitorische Wirkung gegenüber diesen Proteasen. Darüber hinaus 
wurde aus dem Dichlormethanextrakt des Schwammes T. swinhoei, der aus dem Roten 
Meer in Israel gewonnen wurde, Miraziridin A isoliert. Dieses natürliche Peptid war bereits 
aus dem marinen Schwamm Theonella aff. mirabilis isoliert worden. Miraziridin A ist ein 
starker Cathepsin B Inhibitor, der IC50 Wert beträgt 1.4 mg/mL (2.1 M). 
  
Sekundärmetabolite von aus Schwämmen gewonnenen Bakterien wurden ebenfalls 
isoliert und identifiziert. Es konnten 79 Stämme, die zu 20 verschiedenen Gattungen der 
Ordnung Actinomycetales, sowie sieben Stämme, die zu zwei Gattungen der Ordnung 
Sphingomonadales gehören, isoliert werden. Diese Bakterienstämme wurden aus  
ingesamt 18 verschiedenen karibischen Schwämmen kultiviert und mit Hilfe der 16S 
rRNA Sequenzierung bestimmt. Sieben dieser Stämme stellen wahrscheinlich neue Arten 
dar. Rohextrakte ausgewählter Stämme zeigten eine Proteasehemmung gegen die 
Cathepsine B und L, Rhodesain, Falcipain-2 sowie immunmodulatorische Wirkungen wie 
z.B. die Induktion der Cytokinfreisetzung durch menschliche periphere mononukleäre 
Blutzellen. Die Isolate Sphingobium sp. CO105 und Lapillicoccus sp. BA53 wurden für die 
Kultivierung, Extraktion und Aufreinigung von bioaktiven Metaboliten aufgrund der ersten 
vielversprechenden bioaktiven Testergebnisse ausgewählt. Das Isoalloxazin 
Isolumichrom wurde aus dem Stamm Sphingobium sp. CO105 isoliert, welches die 
Protease Rhodesain mit einem IC50-Wert von 0.2 M inhibiert. Für den Stamm 
Lapillicoccus sp. BA53 konnte nachgewiesen werden, dass er p-
Aminosalicylsäuremethylester produziert, der eine Aktivität gegen die Proteasen 
Cathepsin B und L, Falcipain-2 und Rhodesain zeigt. Diese Ergebnisse unterstreichen die 
Bedeutung mariner, Schwamm-assoziierter Bakterien, die bioaktive sekundäre Metabolite 
xiv 
 
mit therapeutischem Potential für die Behandlung von Infektionskrankheiten und 
Funktionsstörungen des Immunsystems produzieren. 
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1. Introduction 
 
1.1. Infection and autoimmunity  
Infection and autoimmunity represent serious problems concerning health care 
worldwide. These include infectious diseases e.g. malaria, trypanosomiasis and 
leishmaniasis, as well as autoimmune diseases such as rheumatoid arthritis. For 
example, the mosquito-borne infectious disease Malaria, caused by the parasite of the 
genus Plasmodium, is endemic in 109 countries and territories in tropical and subtropical 
zones (WHO, 2008). According to the World Health Organization millions of new cases 
are reported every year. An estimated 225 million cases of malaria led to nearly 968,000 
deaths in 2009 (WHO, 2010b). Up to now, several treatments have been used to treat the 
malaria infection, such as chloroquine, sulfadoxine–pyrimethamine and mefloquine, 
treatments that have become ineffective in many countries due to the resistance 
developed by the parasite, especially in the treatment of the infection caused by the 
species Plasmodium falciparum (Marquino et al., 2003, Smithuis et al., 2004).  
 
Another example of infectious diseases is sleeping sickness, which is a neglected tropical 
disease caused by infection with protozoan parasites belonging to the genus 
Trypanosoma (WHO, 2010a). Neglected tropical diseases afflict poor people of 
developing countries. Trypanosomiasis is a vector-borne disease and is usually fatal if left 
untreated. Among several species of the parasite, the species Trypanosoma brucei 
gambiense and Trypanosoma brucei rhodesiense are responsible for the majority of the 
reported cases. Trypanosoma brucei gambiense is endemic in 24 countries of west and 
central Africa and is the cause for more than 90% of the reported cases of sleeping 
sickness. The species Trypanosoma brucei rhodesiense is endemic in 13 countries of 
eastern and southern Africa, representing less than 10% of reported cases (WHO, 
2010a). According to the Weekly Epidemiological Record (WHO, 2006), the total number 
of cases in 2006 was estimated at 50,000 - 70,000. Neglected diseases cause massive, 
though hidden and silent, suffering, and are frequently lethal, albeit not in numbers 
comparable to the deaths caused by HIV/AIDS, tuberculosis or malaria (WHO, 2010a). 
 
Rheumatoid arthritis (RA) is an autoimmune disease, more specifically a chronic 
inflammatory disease characterized by joint swelling, joint tenderness and destruction of 
synovial joints, leading to dramatic loss of life quality due to chronic pain as well as to 
premature mortality (Aletaha et al., 2010). Rheumatoid arthritis disorder affects millions of 
people around the world and is the result of the excessive production of TNF-  (tumor 
 16 
 
necrosis factor alpha), IL-1 (interleukin-1) and IL-6 cytokines by activated T cells, and the 
stimulation of the production of immunoglobulin by B cells (Salliot et al., 2009). In the last 
decade, the availability of therapeutic agents for the treatment of RA has considerably 
increased. TNF blockers have been widely used in the treatment of RA, they have shown 
efficacy in reducing inflammation and joint destruction (Maini and Taylor, 2000, Kang et 
al., 2005). TNF blockers are derived from a recombinant TNF receptor; TNFRSF1B for 
etanercept, anti-TNFA monoclonal antibody for infliximab and adalimumab (Kang et al., 
2005). They are able to inhibit the binding of TNFs to cell-surface TNF receptors. 
However TNF blockers have exhibited side effects and not all patients have shown a 
positive response to the treatment (Kang et al., 2005, Bathon et al., 2000). The use of the 
disease modifying antirheumatic drugs (DMARD), in particular the anchor DMARD 
methotrexate, has enhanced the success of RA management (Choi et al., 2002). There is 
currently no cure for rheumatoid arthritis and it would be ideal to develop and/or improve 
the treatments that can be applied to patients at a stage at which the evolution of joint 
destruction may still be prevented (Aletaha et al., 2010). The lack of effective treatments 
withing the currently available therapies leading to various undesirable effects, 
aggravates the problem and reveals the necessity of finding new therapeutic agents 
and/or improving the currently available treatments of infectious and autoimmune 
diseases. 
 
1.2. Drug discovery approaches 
Different strategies have been developed to find new treatments against infectious and 
autoimmune diseases. These are target-based screening, phenotypic screening, 
modification of natural substances and biology-based approaches (Swinney and Anthony, 
2011) to name only a few. Despite the advances in developing drug candidates over the 
last decade, drug research remains a crucial challenge. Surprisingly, the number of 
drugs, in which new molecular entities (NMEs) were approved by the US Food and Drug 
Administration (FDA), decreased by 50%, when compared with the previous 5 years 
(Paul et al., 2010). The FDA approved 15 new molecular entities in 2010, which lags 
behind the 19 new molecular entities approved in 2009 and the 21 in 2008 (Hughes, 
2009, Hughes, 2010, Mullard, 2011) (Figure 1). Furthermore, most of the therapeutic 
agents approved by the FDA in the last years are treatments against cancer and heart-
related failure. This fact reflects the lack of research aiming to discover new alternative 
therapies against infectious diseases, among them such neglected diseases as, for 
example, the African trypanosomiasis and leishmaniasis.  
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Figure 1. FDA drug approvals since 1996. New molecular entities and biologics license 
applications approved by the US Food and Drug Administration’s (FDA’s) Center for Drug 
Evaluation and Research. Modified from Mullard (2011) 
 
 
1.2.1. Proteases as drug targets 
In this study one of the approaches to discover drug candidates is the targeting of 
proteases, which are relevant drug targets in cancer, cardiovascular, inflammatory and 
infectious disease areas (Otto and Schirmeister, 1997, Turk, 2006). Proteases are 
enzymes that play essential functions in many signaling pathways, the development of 
certain types of cancer as well as in infectious diseases such as malaria and 
trypanosomiasis. Cathepsins B and L are human cysteine proteases involved in tumor 
metastasis (Calkins and Sloane, 1995). Falcipain-2 and rhodesain are proteases 
expressed by the parasites responsible for malaria and African trypanosomiasis. The 
papain-like and the main protease of the SARS coronavirus (SARS-CoV PLpro, SARS-
CoV Mpro) are enzymes essential for the replication of the severe acute respiratory 
syndrome (SARS) coronavirus (Ratia et al., 2006, Anand et al., 2003). Around 32 
protease inhibitors are currently in clinical use and at least 9 are in development. 
Examples are ritonavir, an aspartic protease inhibitor of HIV-1 in clinical use since 1996 
for the AIDS treatment, and boceprevir and telaprevir approved by the FDA in 2011 for 
the treatment of hepatitis C virus infection (Drag and Salvesen, 2010). Most of the 
protease inhibitors reported to date are synthetic molecules developed by structure-based 
design (Turk, 2006). Furthermore, protease inhibitors have also been found in natural 
sources. Miraziridine A (Figure 2), a pentapeptide inhibitor of cathepsins B and L, which 
was isolated from the marine sponge Theonella mirabilis, is one such example (Nakao et 
al., 2000). A family of aeruginosin inhibitors is active against human serine proteases and 
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was isolated from marine sponges and cyanobacterial waterblooms (Ersmark et al., 
2008). Leupeptin was reported from actinomycetes by Hozumi et al. (1972).  
 
 
 
Figure 2. Examples of protease inhibitors isolated from marine sources 
 
 
1.2.2. Search for immunomodulatory agents 
A second relevant aspect in the drug discovery field is the search for immunomodulatory 
agents, such as stimulators of the cells of the immune system such as T cells and NKT 
cells, which play important roles in responses against microbial and tumor antigens. For 
example T cells, the mediators of cellular immunity, recognize the antigens of intracellular 
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microbes and destroy these microbes or the infected cells. T lymphocytes consist of 
functionally distinct populations, such as helper T lymphocytes, cytotoxic T lymphocytes, 
CD4+ regulatory T cells and gamma delta T cells (  T cells). Another example of 
immunomodulatory agents are lectins, which are glycoproteins that participate in 
numerous cellular processes, such as cell communication, host defense, fertilization and 
development (Rangel et al., 2011). NKT cells have been linked to microbial immunity, 
autoimmunity, allergy and cancer and, accordingly, they represent an important 
immunotherapeutic target with immense clinical potential (Pellicci et al., 2011). NKT cell-
mediated regulation of immune responses has been demonstrated to influence a large 
number of disease states. In fact, some forms of human cancer have been correlated to a 
loss of NKT cells, whereas in animal models, stimulation of NKT cells leads to decreases 
in tumor size and growth (Savage et al., 2006). The substance KRN7000 ( GalCer), a 
synthetic analogue of the natural product agelasphin 9b (Figure 3) isolated originally from 
the sponge Agelas mauritianus (Natori et al., 1993), is an NKT cell stimulator and is 
widely used to study the behavior of NKT cells (Park et al., 2010). GSL-1a, a 
glycosphingolipid antigen from Sphingomonas bacteria that is structurally related to 
GalCer, stimulates NKT cells and might be a good candidate for immunotherapy 
(Sullivan and Kronenberg, 2005). A variety of bacterial cells and their fractions have been 
used as immunoadjuvants for the host stimulation against cancer, infectious diseases, 
and other immunological disorders in both clinical and experimental situations (Azuma 
and Seya, 2001). Furthermore, immunoadjuvants are used in vaccination, as well as in 
immune therapy, i.e., the immunostimulatory CpG oligonucleotides (ODNs) induce 
maturation, differentiation and/or proliferation of multiple cell types (Klinman et al., 2010). 
 
 
Figure 3. Examples of NKT cell stimulator glycosphingolipids isolated from marine sources 
 
 
1.3. Natural products as sources of therapeutic agents 
Natural products from terrestrial sources such as plants (roots, latex, leaves, etc.) and 
microbial communities (fungi and bacteria) have yielded an exhaustive supply of 
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biologically active secondary metabolites including the plant related anti-tumor agents 
taxol and colchicine, and several antibiotics such as amphotericin B, tetracycline, and 
erythromycin (Demain, 1999, Dubois et al., 2003, Esquenazi et al., 2008). Before the rise 
of high-throughput screening (HTS), and the post-genomic era, more than 80% of drug 
substances were natural products or inspired by a natural compound (Harvey, 2008, 
Butler, 2008). Even though terrestrial environments have served as source of many drugs 
currently in clinical use, terrestrial environments have been exhaustively studied and, 
during the last years, the search for new therapeutic agents has been directed to other 
natural sources such as marine animals and their associated microorganisms.  
 
Since the 1960’s, more than 20,000 compounds have been discovered from marine 
sources (Hu et al., 2011). The organisms producing these marine natural products are 
divided into three major biological classes: microorganisms, algae and marine 
invertebrates. Between 1985 and 2008, approximately 75% of the compounds were 
isolated from marine invertebrates belonging to the phyla Porifera (sponges) and 
Coelenterate (coral) (Figure 4) (Hu et al., 2011).  
 
 
 
Figure 4. The number of novel compounds isolated from marine invertebrates between 1985 and 
2008. Modified from Hu et al. (2011) 
  
 
Currently there are four marine drugs approved by the FDA in the US Pharmacopeia, 
namely cytarabine, vidarabine, ziconotide and halaven (Mayer et al., 2010, Huyck et al., 
2011) (Figure 5). Cytarabine is a synthetic pyrimidine nucleoside that was developed from 
Protozoa Porifera Coelenterate Bryozoa Mollusca Echinodermata Annelida Chordata
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spongothymidine, a nucleoside originally isolated from the Caribbean sponge Tethya 
crypta, and is used in the treatment of acute lymphocytic leukemia (Molinski et al., 2009). 
Vidarabine, a purine nucleoside developed from the spongouridine, originally isolated 
from the Caribbean sponge Tethya crypta, is currently obtained from Streptomyces 
antibioticus (Shen et al., 2009), and is active against the herpes simplex encephalitis 
virus; it has been in clinical use for many years. Ziconotide is the equivalent of a naturally 
occurring 25-amino acid peptide, v-conotoxin MVIIA, isolated from the venom of the fish-
hunting marine snail Conus magus and is used in the management of severe chronic pain 
in patients with AIDS (Staats et al., 2004). The most recent marine metabolite approved 
by the FDA is halaven, a synthetic form of a chemotherapeutically active compound 
derived from the sponge Halichondria okadai, which is active in the treatment of 
advanced breast cancer (Huyck et al., 2011).  
 
 
 
Figure 5. Marine natural products or derivatives approved for clinical use by the FDA 
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1.3.1. Marine sponges  
Marine sponges (phylum Porifera) are among the oldest multicellular animals 
(Metazoans) (Li et al., 1998). The Porifera are divided into three classes: the Calcarea 
(calcareous sponges), the Hexactinellida (glass sponges) and the Demospongiae 
(demosponges). The latter is the most comprehensive and variable class covering about 
95% of all sponge species (Brusca and Brusca, 1990). More than 6,000 species have 
been described for this phylum, classified in 25 orders, 127 families and 682 genera 
(Brusca and Brusca, 1990, Hooper and Van Soest, 2002). Marine sponges lack neurons 
or any other kind of nervous tissue. Instead, they have a unique bauplan, characterized 
by different reproductive modes as well as cellular totipotency and mobility balancing the 
lack of true tissues and organs (Brusca and Brusca, 1990). Sponges are highly variable in 
color and shape encompassing different morphotypes (i.e. tube, vase, rope, ball, 
encrusting) (Figure 6) that vary with exposure to currents and depth. Marine sponges are 
found mostly in tropical and subtropical benthic habitats, but also thrive in higher latitudes 
as well as in freshwater lakes and streams (Brusca and Brusca, 1990, Hooper and Van 
Soest, 2002). Marine sponges with an exceptionally rich chemistry have been the source 
of several bioactive secondary metabolites. To date, more than 5300 different products 
have been isolated from sponges and their associated microorganisms (Laport et al., 
2009). Blunt et al. (2010) in a Natural Product Report review, described 287 new 
compounds from marine sponges isolated in 2009. Remarkable examples of bioactive 
secondary metabolites isolated from marine sponges are hemiasterlin (E7974) and 
discodermolide (Figure 7). Hemiasterlin (E7974), is a cytotoxic tripeptide originally 
isolated from the marine sponge Hemiasterella minor, currently in Phase I trial (Talpir et 
al., 1994). The polyketide natural product discodermolide, isolated from the marine 
sponge Discodermia dissoluta has potent cytotoxicity to human and murine cell lines 
(Kingston et al., 2011). Certain marine sponges have been recognized as potentially rich 
sources of various bioactive compounds. According to the MarinLit database, around 319 
compounds have been reported from the genus Xestospongia, 244 compounds from the 
genus Theonella, 222 compounds from the genus Halicondria and 118 metabolites have 
been reported from the genus Aplysina among other sponges. Of special interest to this 
project are the species Amphimedon compressa, Aiolochroia crassa and Theonella 
swinhoei for the protease inhibitory activity of their crude extracts observed in previous 
studies (Degel, 2006). 
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Figure 6. Demosponges: a. Agelas clathrodes, b and c two differently colored morphotypes of the 
sponge Aiolochroia crassa, d. Amphimedon compressa, e. Aplysina fistularis, f. Discodermia 
dissoluta, g. Dragmacidon reticulata, h. Ircinia felix, i. Monanchora arbuscula, j. Mycale laevis, k. 
Niphates digitalis and l. Xestospongia muta. Sponges a - e and j - l were photographed by Dr. 
Hilde Angermeier from the University of Würzburg and sponges f - i by Prof. Sven Zea from 
INVEMAR, Colombia.  
 
a. b. c.
d. e. f.
g. h. i.
j. k. l.
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Figure 7. Examples of bioactive compounds isolated from marine sponges 
 
 
Amphimedon compressa is a marine sponge (phylum Porifera, class Demospongiae) 
abundant in Florida, the Bahamas and the Caribbean (Angermeier, 2011), known to 
produce useful natural products, such as cytotoxins and antifouling agents (Jeanteur et 
al., 2006). A. compressa belongs to the family Haliclonidae, whose color varies from 
brown with green shades to red or purple-brown (Albrizio et al., 1995). At least seventeen 
secondary metabolites have been reported from the sponge Amphimedon compressa 
such as 2-hydroxydocosanoic acid, 2-hydroxytricosanoic acid (Carballeira and Lopez, 
1989) (Figure 8), 17-tricosenal, 21-octacosenoic acid, 19-pentacosenal, 19-hexacosenal, 
16-tricosenoic acid, 18-tricosenoic acid, 16-pentacosenoic acid, 18-pentacosenoic acid, 
19-pentacosenoic acid, 20-hepacosenoic acid (Carballeira et al., 1992), methyl 2-
methoxyhexadecanoate, 8,8'-dienecyclostellettamine (Carballeira et al., 1998), 8,8'-
dienecyclostellettamine (Xu et al., 2007), amphitoxin (Albrizio et al., 1995) and 
amphiceramides A and B (Costantino et al., 2009). Amphitoxin, for example, showed a 
broad spectrum of biological activities including antimicrobial and anti-feedant activities 
(Jeanteur et al., 2006). 
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Figure 8. Examples of secondary metabolites isolated from the sponge A. compressa 
 
 
Aiolochroia crassa is a marine sponge of the order Verongida, which is massive, with 
lobate or, more rarely, ramose processes, yellow to violet in color (Ciminiello et al., 1995). 
Aiolochroia crassa is characterized chemically by a series of secondary brominated 
metabolites, biogenetically arising from bromotyrosines (Albrizio et al., 1994). Around 
twenty compounds have been isolated from the sponge Aiolochroia crassa (Figure 9) 
including N-methyl-aerophobin-2, aerophobin-1, aerophobin-2, purealidin L, isofistularin-3 
(Assmann et al., 1998), araplysillin III, hexadellin C (Hamann et al., 1999). Fistularin-3 
was active in vitro against Mycobacterium tuberculosis (Hamann et al., 1999). A recent 
study of the structural and physico-chemical properties of three-dimensional skeletal 
scaffold of the marine sponge Aiolochroia crassa, showed that these fibrous scaffolds 
have a multilayered design and are made of chitin (Ehrlich et al., 2010). Natural polymers 
like chitin are widely used in the biomedical field because of their high biocompatibility 
and the enriched functionalities being capable of integrating well with a variety of ligands 
(Rejinold et al., 2011). 
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Figure 9. Examples of secondary metabolites isolated from the sponge A. crassa 
 
 
The marine sponge Theonella swinhoei, a marine sponge of the order Lithistida is 
typically found in deeper waters and caves of tropical oceans. T. swinhoei has a 
structurally massive and rigid morphology. Its skeleton consists of fused or interlocked 
spicules, called desmas (Jeanteur et al., 2006). The sponge Theonella swinhoei has 
shown to be a source of anti-protease and anti-HIV secondary metabolites (Fusetani et 
al., 1999, Plaza et al., 2010). The marine sponge Theonella aff. mirabilis, has been 
reported to contain the protease inhibitor miraziridine A (Nakao et al., 2000) and the 
papuamides A and B (Figure 10) with anti-HIV properties (Ford et al., 1999). Miraziridine 
A is a secondary metabolite of particular interest due to its three structural elements (i) 
(2R,3R)-aziridine-2,3-dicarboxylic acid, (ii) (3S,4S)-4-amino-3-hydroxy-6-methylheptanoic 
acid (statine) and (iii) (E)-(S)-4-amino-7-guanidino-hept-2-enoic acid (vinylogous arginine 
residue), which are responsible for the inhibition of three different classes of proteases, 
such as serine (e.g. trypsin), cysteine (e.g. cathepsins B and L) and aspartyl proteases 
(e.g. pepsin) (Schaschke, 2004). The sponge Theonella swinhoei has been found to 
contain antifungals including cyclolithistide A, theonegramides and theopalauamide, as 
well as paltolides and cytotoxic polytheonamides (Schaschke, 2004). 
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Figure 10. Examples of secondary metabolites isolated from the sponge T. swinhoei 
 
1.3.1.1. Microbial diversity of marine sponges 
Many marine sponges are associated with dense and phylogenetically diverse microbial 
consortia including bacteria, archaea and single-celled eukaryotes (fungi and 
microalgae), that can account for nearly half of the animal’s biomass (Hentschel et al., 
2006, Taylor et al., 2007). Sponges are filter-feeders capable of processing enormous 
volumes of seawater, providing a rich source of microorganisms. Two different sponge 
types in respect of their association with bacteria have been called “high-microbial-
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abundance” (HMA) and “low-microbial-abundance” (LMA) sponges (Figure 11) 
(Hentschel et al., 2003). Bacterial populations in HMA are in the range of 6.4 x 108 – 1.5 x 
109 bacteria g-1 (Vacelet and Donadey, 1977, Hentschel et al., 2006). So far, more than 
25 bacterial phyla have been reported from sponges (Webster and Taylor, 2011, Schmitt 
et al., 2011) (Figure 12). The dominant bacterial taxa in marine sponges are 
Proteobacteria, Actinobacteria, Chloroflexi, Firmicutes, Acidobacteria and Cyanobacteria 
(Fieseler et al., 2004, Scheuermayer et al., 2006, Taylor et al., 2007).  
 
 
 
Figure 11. Transmission electron micrographs of sponge tissue. a. sponge Xestospongia muta 
(HMA) and b. sponge Amphimedon compressa (LMA). The scale bars represent 5 m each. 
Abbreviations: N, nucleus; Sc, sponge cell; B, bacteria (Angermeier, 2011) 
 
 
  
a. b.
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Figure 12. Phylogenetic distribution of sponge-associated bacteria. Modified from Schmitt and 
Hentschel (2008) 
 
 
Marine microorganisms are well-known for being capable of producing bioactive 
secondary metabolites. Between 1985 and 2008, around 850 compounds were isolated 
from marine microorganisms including bacteria, fungi and phytoplankton (Hu et al., 2011) 
(Figure 13). A wide range of chemical and functional diversity has been observed among 
bioactive compounds such as polyketides, alkaloids, fatty acids, peptides and terpenes 
(Thomas et al., 2010). Most of the compounds isolated from marine microorganisms have 
shown biological properties such as antimicrobial, antitumor and anticancer activities. The 
phylum Actinobacteria dominates in the production of therapeutic compounds followed by 
Proteobacteria. Among fungi, members of the Ascomycota are predominant producers of 
bioactive molecules and members of Deuteromycota are also a potential group for 
exhibiting bioactivity (Thomas et al., 2010). 
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Figure 13. The number of novel compounds isolated from marine microorganisms between 1985 
and 2008. Modified from Hu et al. (2011) 
 
 
Of special interest to this PhD project are the members of the phylum Actinobacteria 
(Figure 14) which have been identified in sponges both by cultivation and cultivation-
independent approaches (Webster et al., 2001, Hentschel et al., 2002, Kim et al., 2005, 
Montalvo et al., 2005, Jiang et al., 2008, Pimentel-Elardo et al., 2010, Abdelmohsen et 
al., 2010, Tabares et al., 2011b). Several genera have been described for this order, 
namely Streptomyces, Micromonospora, Nocardia, Nocardiopsis, Arthrobacter, and 
Microbacterium. Actinomycetes have been described as potential sources of secondary 
metabolites. For example, the cebulactams A1 and A2 have been reported from the first 
obligate marine strain of the genus Saccharopolyspora (Pimentel-Elardo et al., 2008). 
Streptomyces has been shown to be the most prolific producer of bioactive metabolites 
accounting for the majority of the reported metabolites with antibiotic properties 
(Dharmaraj, 2010). Around 80% of all microbial-derived secondary metabolites are 
produced by members of the order Actinomycetales with the genus Streptomyces 
accounting for approximately 50%. For instance, four new tetromycin derivatives with 
antitrypanosomal and protease inhibitory activities have been isolated from the strain 
Streptomyces axinellae, which has been cultivated from the Mediterranean sponge 
Axinella polypoides (Pimentel-Elardo et al., 2011). Actinobacteria, and specifically 
members of the order actinomycetes, are, in fact, quite abundant in the marine 
environment (Stach and Bull, 2005). A number of obligately marine actinomycete species 
and genera have been described which indicates true forms of adaptation to the marine 
environment rather than simply being washed into the ocean as spores from terrestrial 
soils. The actinomycetes are of particular relevance due to their unmatched capacity to 
produce novel, and bioactive secondary metabolites. About 7,000 compounds have been 
isolated from this bacterial taxon alone (Jensen et al., 2005). The anticancer compounds 
salinosporamide and sporolide from the actinomycete Salinispora tropica (Fenical et al., 
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2009, Buchanan et al., 2005), as well as the antitumor antibiotic marinomycin from the 
obligately marine genus Marinispora (Kwon et al., 2006), are examples of metabolites 
from marine actinomycetes (Figure 15). 
 
 
 
Figure 14. Various morphologies of actinomycete strains. a. Gordonia terrae, b. Lapillicoccus sp., 
c. Micromonospora coxensis, d. Saccharopolyspora shandongensis, e. Streptomyces chartreusis, 
f. Streptomyces sp. and g. Streptomyces sp. Photos: P. Tabares 
 
 
Figure 15. Examples of bioactive secondary metabolites isolated from actinomycete strains 
a. b. c.
d. e. f. g.
 32 
 
Other interesting taxa associated with marine sponges are bacteria of the order 
Sphingomonadales, which are yellow-pigmented, Gram-negative, rod-shaped bacteria 
that contain glycosphingolipids (GSLs) in their cell envelope and were first described by 
Yabuuchi et al. (1990). Glycosphingolipids are a class of compounds that have been 
shown to be potent stimulators of natural killer T cells (Kinjo et al., 2005, Sriram et al., 
2005, Mattner et al., 2005). Long et al (2007) reported the synthesis and evaluation of 
stimulatory properties of the GSL-1 to GSL-4 series of glycosphingolipids isolated from 
the Sphingomonadaceae family. GSL-1 was found to be a potent NKT cell stimulator. 
GSL-4 (Figure 16), a metabolite isolated from a Sphingomonas strain has been 
previously found to have NKT cell stimulatory properties (Sriram et al., 2005). 
Interestingly, Laroche et al. (2007) suggested that glycolipids of the marine sponge 
Plakortis simplex are produced by microbial symbionts rather than by the sponge itself. 
Sphingomonads also produce other types of secondary metabolites, for example the 
diketopiperazine glionitrin B, was reported to be produced using a microbial co-culture of 
the bacterium Sphingomonas sp. KMK-001 and the fungus Aspergillus fumigatus KMC- 
901 (Park et al., 2011). 
 
 
 
Figure 16. Examples of secondary metabolites isolated from Sphingomonas strains 
 
 
Other interesting taxa of marine organisms associated with marine sponges that have a 
pharmacological significance are Cyanobacteria e.g. Lyngbya, Oscillatoria, Symploca, 
Calothrix, Leptolyngbya, Dichothrix, Geitlerinema, Schizothrix, Aphanothece, Blennothrix 
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and Synechocystis (Nagarajan et al., 2011). Cyanobacteria are known to produce diverse 
structural classes of metabolites. Malyngamide H (Figure 17), is an ichthyotoxic amide 
isolated from the marine Cyanobacterium Lyngbya majuscula (Orjala et al., 1995). 
Isomalyngamide A, a fatty acid amide isolated from the Taiwanese Lyngbya majuscula, 
was found to have therapeutic potential against tumor cell migration (Chang et al., 2011). 
It is known, for example, that the occurrence of scytonemins, which are metabolites 
composed of either an aminocyclohexenone or an aminocyclohexenimine ring, containing 
amino acid or amino alcohol substituents, is restricted to cyanobacteria or cyanobacterial 
lichens (Klisch and Hader, 2008). Scytonemins are interesting due to their 
pharmacological potential as modulator of cell cycle control and inflammation (Stevenson 
et al., 2002).  
 
 
 
Figure 17. Examples of bioactive compounds from marine Cyanobacteria 
 
 
In recent years, the attention of scientific researchers has been also directed toward the 
production of secondary metabolites by marine fungi, which have been shown to possess 
an interesting and unique chemistry, as well as biological properties (Rateb and Ebel, 
2011). According to Rateb et al. (2011) more than 1,000 compounds have been isolated 
from marine fungi. For instance, fourteen anthracenedione derivatives (Figure 18) were 
separated from the secondary metabolites of the mangrove endophytic fungus 
Halorosellinia sp. and exhibited potent anticancer activity (Zhang et al., 2010). 
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Figure 18. Examples of bioactive compounds from marine fungi 
 
 
Thus, marine sponges and their associated microorganisms are sources of bioactive 
secondary metabolites, as yet underexplored. The focus of this PhD thesis was directed 
towards the isolation of bioactive secondary metabolites from the sponges A. compressa, 
A. crassa and T. swinhoei, as well as from putatively novel actinomycete and 
sphingomonad isolates associated with different Caribbean sponges. The discovery of 
novel bacterial communities from sponges increases the likelihood of finding innovative 
chemical compounds with new moieties and biological activities relevant to develop 
alternative therapeutic agents against different diseases. 
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2. Aims  
 
The aim of this PhD thesis was to identify bioactive secondary metabolites in marine 
sponges and their associated bacteria. By following a bioactivity-guided scheme, crude 
extracts, fractions and pure compounds were tested for their antimicrobial and anti-
protease activities, as well as for their immunomodulatory responses. The project is 
divided into two parts as follows: 
 
2.1. Searching for bioactive secondary metabolites from marine sponges previously 
shown to exhibit anti-protease activity. Following the preparation of organic crude extracts 
and their testing for bioactivity, the structure of the bioactive compounds was elucidated 
by means of chromatographic, spectroscopic and spectrometric techniques. 
 
2.2. Searching for bioactive secondary metabolites from bacteria associated with 
Caribbean marine sponges. This project involved the establishment of strain collections, 
the screening of organic extracts for bioactivities, the molecular phylogenetic identification 
of novel isolates and the elucidation of the structure of the bioactive compounds by using 
chromatographic, spectroscopic and spectrometric techniques. 
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3. Materials and Methods 
  
This thesis was conducted in the research laboratories of Prof. Ute Hentschel (Dept. of 
Botany II, Julius-von-Sachs Institute for Biological Sciences), Prof. Thomas Hünig 
(Institute for Virology and Immunobiology), and Prof. Tanja Schirmeister (Institute of 
Pharmacy and Food Chemistry). Experimental procedures of this PhD project were 
performed by myself-unless stated otherwise. Molecular biology and microbiology 
procedures, as well as the preparation of crude extracts from bacterial biomass were 
performed in Prof. U. Hentschel’s laboratory, immunology methods were performed in 
Prof. T. Hünig’s laboratory with the guidance of the doctoral candidate Paula Römer and 
the technical assistance of Susanne Berr. Preparation of crude extracts from sponge 
biomass, fractionation of all crude extracts and structure elucidation of metabolites were 
conducted in Prof. T. Schirmeister´s laboratory. Protease inhibitory assays were 
performed by the technical assistant Cornelia Heindl in Prof. Schirmeister’s group. 
Moreover, antimicrobial bioactivity testing including antibacterial, biofilm inhibition, 
antifungal, antileishmanial and antitrypanosomal assays, as well as cytotoxicity assays 
were performed by the SFB 630 collaboration partners: TP Z1 (Dr. Tobias Ölschläger, PD 
Dr. August Stich and Prof. Lorenz Meinel, U. Würzburg). 
 
3.1. Collection and organic extract preparation from sponge biomass 
3.1.1.  Sponge collection 
The marine sponges Amphimedon compressa and Aiolochroia crassa were collected by 
the SCUBA diver Dr. Hilde Angermeier (Würzburg University) at depths of 3-20 m in the 
Bahamas in May 2008 (GPS: 26° 27' 3.25" N, 77° 54' 14.59" W). The marine sponge 
Theonella swinhoei was collected by the SCUBA diver Prof. Micha Ilan (Tel Aviv 
University) in the Red Sea in Eilat (Israel) at a depth of 3 m in December 2004 (GPS: 
29º30' 07'' N; 34º55' 02'' W). Sponge material was frozen and transported to the 
laboratory and subsequently stored at -80 ºC. 
 
3.1.2. Organic extract preparation  
30 g of biomass of the sponges Amphimedon compressa, Aiolochroia crassa and 
Theonella swinhoei were lyophilized with a Christ ALPHA II-12 freeze dryer. 10 g of the 
dried biomass from each sponge were extracted successively with cyclohexane, 
dichloromethane and methanol (1 L of each solvent) to obtain milligram amounts of the 
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three different crude extracts per sponge. Obtained crude extracts were submitted to 
bioactivity testing. 
 
3.1.3. Fractionation of crude extracts 
LC-MS experiments were performed on an Agilent 1100 LC/MSD trap with a HPLC 
system 1100, Agilent, using a Phenomenex Jupiter 4  Proteo 90A RP C18 column (4.6 x 
150 mm) or using the ACQUITY UPLC®/Q-TOF System (Column: BEH C18, 1.7 m, 2.1 x 
50 mm). Column chromatography was performed on Sephadex HL-20. Solvents used for 
extraction and column chromatography were glass-distilled prior to use; the solvents used 
for LC-MS were HPLC grade. 1H- and 13C-NMR spectra were obtained on Bruker Avance 
400 MHz or Bruker DMX 600 MHz spectrometers, in MeOD;  in ppm. 
 
The crude cyclohexane extract of the sponge A. compressa (Ah) was fractionated by 
using normal phase flash column chromatography, using a gradient system with hexane 
and ethyl acetate. Milligram amounts of fractions Ah1, Ah2, Ah3, Ah4 and Ah5 were 
collected and submitted for bioactivity testing. 
 
The crude methanol extract from A. compressa (Am) was fractionated using column 
chromatography to obtain three fractions (Am1, Am2 and Am3). Fractions Am1 and Am2 
were combined and given the name Am1. After preparative HPLC analysis of the sub-
fraction Am1, seven sub-fractions (Am1a to Am1g) were collected and submitted to 
bioactivity testing. 
 
Prepared extracts from the sponge T. swinhoei were subjected to reverse phase LC-MS, 
using H2O (0.1% formic acid)/MeCN (0.1% formic acid) gradient (60% H2O for 5 min, 60-
5% H2O in 20 min and 5% H2O for 15 min), and the peaks were detected at 254 nm. 
Crude dichloromethane extract (Td) containing the [M+H]+ peak for miraziridine A was 
subjected to column chromatography on sephadex (eluent: methanol) to generate three 
sub-fractions (Td-1, Td-2 and Td-3). The three sub-fractions obtained were subsequently 
analyzed by LC-MS; Td-3 contained the [M+H]+ peak for miraziridine A. Furthermore, Td-
3 and synthetic miraziridine A, synthesized according to Schaschke (2004), were 
subjected to LC–MS, H2O/MeCN gradient (100% H2O for 3 min, 100-0% for 32 min, 0-
100% for 10 min), and detection at 220 and 254 nm. 
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3.2. Cultivation and identification of bacteria associated with marine sponges, and 
bioactivity-guided fractionation of crude extracts from bacterial isolates 
3.2.1. Sponge collection 
The first collection, consisting of the first group of sponges (Aplysina fistularis, Plakortis 
sp., Amphimedon compressa, Aiolochroia crassa, Agelas clathrodes, Agelas cerebrum, 
Ircinia felix, Scopalina ruetzleri, Erylus formosus, Chondrilla nucula and Aplysina archeri) 
was obtained by SCUBA diver Dr. Hilde Angermeier, at depths of 3-20 m in the Bahamas 
in May 2008 (GPS: 26° 27' 3.25" N, 77° 54' 14.59" W). The second collection, consisting 
of sediments, seawater, and the second group of sponges (Agelas clathrodes, Aplysina 
insularis, Agelas tubulata, Biemna cribaria, Aiolochroia crassa, Discodermia dissoluta, 
Scopalina ruetzleri, Dragmacidon reticulata, Ircinia felix, Monanchora arbuscula and 
Plakinastrella onkodes) was collected by SCUBA diver Sven Zea (Institute of Marine and 
Coastal Research "José Benito Vives de Andreis", INVEMAR) at depths of 11-23 m in El 
Morro, Santa Marta Bay, Colombia (GPS: 11° 14' 59.04" N, 74° 13' 44.47" W) in 
December 2008. The sponges were transferred to plastic bags containing seawater and 
immediately transported to the laboratory. The sponge specimens were rinsed in sterile 
seawater, cut into pieces of ca. 1 cm3, and then thoroughly homogenized in a sterile 
mortar with 10 volumes of sterile seawater. The supernatant was diluted in ten-fold series 
(10-1, 10-2, 10-3) and subsequently plated out on agar plates. The same protocol was 
repeated for sediment and seawater samples. Preparation of sponge homogenates and 
cultivation and isolation of Colombian bacterial isolates were done by myself in a 
research stay in INVEMAR and in the Universidad Tecnológica de Pereira, Colombia. 
 
3.2.2. Bacterial isolation  
Six different media were used for the isolation of Actinobacteria, such as M1 (1 L artificial 
sea water (ASW) containing 10 g starch, 4 g yeast extract, 2 g peptone, 18 g Bacto Agar 
and 1 L ASW), M2 (1 L ASW was made up of 6 mL of 100% glycerol, 1 g arginine, 1 g 
K2HPO4, 0.5 g MgSO4 and 18 g Bacto Agar) (Mincer et al., 2002), ISP medium 2 (1 L 
ASW containing 4 g yeast extract, 10 g malt extract, 4 g dextrose and 18 g Bacto Agar) 
(Shirling and Gottlieb, 1966), M7 (1 L ASW containing 2 g peptone, 0.1 g asparagine, 4 g 
sodium propionate, K2HPO4, 0.1 g MgSO4, 0.0001 g FeSO4, 5 g glycerol, 20 g NaCl and 
18 g Bacto Agar) (Webster et al., 2001), NaST21Cx (solution A: 750 mL of artificial 
seawater containing 1 g K2HPO4 and 10 g Bacto Agar and solution B: 250 mL artificial 
seawater containing 1 g KNO3, 1 g MgSO4, 1 g CaCl2.2H2O, 0.2 g FeCl3, and 0.1 g 
MnSO4·7H2O) (Magarvey et al., 2004) and Oligotropic medium (1 L ASW containing 0.5 g 
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tryptone, 0.1 g sodium glycerophosphate, 0.05 g yeast extract and 12 g Bacto Agar) 
(Santavy et al., 1990). Heat shock (95 ºC for 10 min) and incubation with 1.5% phenol at 
30 ºC for 30 min were applied to the sponge homogenates to select for spore-forming 
actinomycetes and rare actinomycete genera. All plates were incubated and observed for 
growth of colonies for 6-8 weeks. All media were supplemented with the following 
antibiotics: cycloheximide (100 g/mL), nystatin and nalidixic acid (25 g/mL) to inhibit the 
growth of fungi and Gram-negative bacteria. Sphingomonads were isolated on M1, ISP 
medium 2 and Oligotropic medium. The isolates from the Bahamas are abbreviated as 
“BA” and those from Colombia as “CO.” 
 
3.2.3. Molecular identification and phylogenetic analysis 
The 16S rRNA genes from all Bahamian sponge isolates were amplified, cloned and 
sequenced according to Hentschel et al. (2001) using the universal primers 27F and 
1492R (Lane, 1991). Isolates from the Colombian sponges were first sorted into groups 
according to their morphological characteristics. Restriction length fragment 
polymorphism (RFLP) analysis was then performed on all isolates to reduce strain 
replication. Following 16S rRNA gene amplification using the universal primers 27F and 
1492R (Lane, 1991) and 341F and 907R (Muyzer et al., 1993), the PCR products were 
digested with the restriction enzymes HaeIII and MspI for 2 h. One to two isolates from 
each RFLP group were selected for 16S rRNA gene sequencing.  
 
Chimeric sequences were identified using the Pintail program (Ashelford et al., 2005). 
Sequence alignment and phylogenetic analysis were performed using the ARB software 
package (Ludwig et al., 2004). The genus-level affiliation of the isolates was validated 
using the Ribosomal Database Project Classifier (Wang et al., 2007). Tree construction 
was conducted using neighbor-joining algorithm (Jukes-Cantor correction) with bootstrap 
values based on 1000 replications. The 16S rRNA gene sequences of the putatively 
novel isolates were deposited in GenBank under the accession numbers indicated in 
parentheses: BA21 (HM005239), BA53 (HM005240), CO58 (HM005241), CO104 
(HM005242), CO105 (HM005243), CO132 (HM005244), CO155 (HM005245). All other 
16S rRNA gene sequences (Table 5 and Table 6) were deposited in GenBank under the 
accession numbers: HQ398366-HQ398418. 
 
3.2.4. Organic extract preparation of selected isolates 
Sixteen strains were selected based on phylogenetic novelty (4 actinomycetes, 3 
sphingomonads) or their affiliation to clades for which secondary metabolites had not yet 
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been reported (9 strains). The isolates were cultured in 100 mL Erlenmeyer flasks each 
containing 20 mL liquid M1 medium. The cultures were grown for 4-21 days at 30°C while 
shaking at 150 rpm and three mL culture aliquots were taken at different points in time 
(day 4, 7, 14, 21). 1.5 mL methanol was added to each culture aliquot for cell lysis and 
shaking was continued at 150 rpm for two hours at room temperature (E. Bühler shaker, 
SM 30). The broths were centrifuged in 15 mL-Falcon tubes at 5000 rpm for 15 min at 
room temperature (Megafuge 1.0R, Heraeus) and the supernatants were dried under 
reduced pressure using a rotary evaporator (Heidolph, Germany). Media control, using 
non-inoculated M1, was extracted using the same method as above.  
 
A subset of eleven strains was also grown on M1 agar plates (three square plates per 
strain with approximately 120 mm diameter each) at 30 ºC for 7-10 days. Biomass was 
removed from the plates together with the agar by cutting it into small pieces and was 
macerated overnight with a sufficient volume of ethyl acetate to submerge the agar 
pieces. Extraction with ethyl acetate of the macerated agar was repeated, and the 
macerations were subsequently filtered by gravity using a Whatman filter paper No. 1. 
The filtrates were combined and dried under reduced pressure by rotary evaporation. 
Media control, using uninoculated M1 agar, was extracted using the same method as 
above.  
 
3.2.5. Organic extract preparation of isolates Lapillicoccus sp. BA53, Sphingobium 
sp. CO132 and Sphingobium sp. CO105 
Based on phylogenetic novelty and biological activity, the Bahamian strain Lapillicoccus 
sp. BA53 and the Colombian strains Sphingomonas sp. CO105 and Sphingobium sp. 
CO132 were selected for cultivation, extraction and further fractionation (Table 1). Strains 
Lapillicoccus sp. BA53 and Sphingobium sp. CO105 were grown on M1 agar plates 
(square plates with approximately 120 mm diameter each) at 30 ºC for 7-10 days. The 
biomass was removed from the plates together with the agar by cutting it into small 
pieces and was transferred to 1 L Erlenmeyer flasks and macerated overnight with 500 
mL ethyl acetate (per flask) to submerge the agar pieces. Extraction with ethyl acetate of 
the macerated agar was repeated and the macerations were subsequently filtered by 
gravity using a Whatman filter paper No. 1. The filtrates were combined and dried by 
rotary evaporation. Strains Lapillicoccus sp. BA53 and Sphingobium sp. CO132 were also 
cultured in thirteen and nineteen L liquid M1 medium, respectively. The cultures were 
grown for 7-10 days (depending on their growth rate) at 30 °C while shaking at 150 rpm. 
Amberlite XAD-16 resin (Sigma, Germany) was added to the cultures (30 g/L) and 
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shaking was continued at 150 rpm for two hours at room temperature (E. Bühler, SM 30). 
The broths were filtered and secondary metabolites were eluted from the amberlite XAD-
16 using acetone and methanol successively. The resulting crude extracts were dried 
under reduced pressure using a rotary evaporator (Heidolph, Germany) to obtain around 
400 - 1500 mg each (Table 1). 
 
Table 1. Preparation of crude extracts from active and novel strains 
 
 
3.2.6. Bioactivity-guided fractionation of extracts from isolates Lapillicoccus sp. 
BA53 and Sphingobium sp. CO105 
3.2.6.1. Strain Lapillicoccus sp. BA53 
600 mg of the dried crude extract obtained from the solid culture of strain Lapillicoccus 
sp. BA53 were subjected to preparative RP HPLC (Agilent, Prostar), using H2O/MeOH 
gradient (90-0% H2O in 40 min, 0-100% H2O in 0.5 min, 100-90% H2O in 10 min and 90% 
H2O for 10 min), to yield 44 fractions named BA53-1 to 44. The 44 fractions thus obtained 
were combined according to their thin-layer chromatography (TLC) profiles (254 and 366 
nm) with CH3Cl/MeOH (45:5, v/v) to provide 11 fractions named BA53a to k, which were 
tested for their anti-protease and immunomodulatory activities, as described in detail in 
section 3.3. The fraction BA53h was further partitioned by preparative RP HPLC using 
H2O/MeOH gradient (50-0% H2O in 14 min, 100% MeOH for 3 min, 0-50% H2O in 8 min 
Strain Activity 
Cultivation 
(M1 medium) 
Crude extract  
(mg) 
Actinomycetes 
   
Lapillicoccus sp. BA53 Induction of IFN-  and IL-2 
release  
300 agar plates for 10 
days 
644 
 
 
13 liter medium for 7 
days  
1000 
 
Sphingomonads 
  
 
Sphingobium sp. CO105 PBMC proliferation and 
induction of IFN- , IL-2 
and IL-10 release 
200 agar plates for 10 
days 
423 
 
   
Sphingobium sp. CO132  Inhibition of rhodesain, 
IFN- , IL-2 and IL-10 
release 
19 liter medium for 10 
days 
1500 
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and 50% H2O for 2 min) to obtain BA53h-1 and 2, which were further tested for their 
protease inhibitory activity. The fraction BA53h-1 and 2 were further partitioned by 
preparative RP HPLC and the resulting sub-fractions were tested for their protease 
inhibitory activity. According to the TLC and HPLC profiles, active sub-fraction BA53h2-12 
(2 mg) was a nearly pure compound.  
 
1000 mg of the dried crude extract obtained from the liquid culture of strain Lapillicoccus 
sp. BA53 were subjected to preparative RP HPLC (Agilent, Prostar), using H2O/MeOH 
gradient (flow: 7 mL/min, 90-0% H2O in 40 min, 0-100% H2O in 0.5 min, 100-90% H2O in 
4.5 min and 90% H2O for 10 min), to yield 40 fractions named BA53L1 to 40, which were 
submitted to anti-protease bioactivity testing. The active fractions BA53L30, BA53L33, 
BA53L34, BA53L36 and BA53L37 were subjected to semi-preparative RP HPLC (Agilent 
1100), performed using H2O + 0.05% TFA and CH3CN as the solvents and the following 
gradient: flow 2.5 mL/min, 90-0% H2O + 0.05% TFA in 20 min, 100% CH3CN for 4 min, 0-
50% H2O + 0.05% TFA in 4 min and 50-90% H2O + 0.05% TFA in 2 min. The fractions 
and nearly pure compounds thus obtained were submitted to bioactivity testing and NMR 
and MS analysis.  
 
3.2.6.2.  Strain Sphingobium sp. CO105 
400 mg of the dried crude extract obtained from strain Sphingobium sp. CO105 were 
subjected to preparative RP HPLC (Agilent, Prostar), using H2O/MeOH gradient (90-0% 
H2O in 30 min, 100% MeOH for 5 min, 0-90% H2O in 0.5 min and 90% H2O for 14.5 min), 
to yield sixteen fractions named CO105-1 to 34. The fraction named CO105-32, active 
against the protease rhodesain, was further partitioned by preparative RP HPLC using 
H2O/MeOH gradient (90-0% H2O in 50 min, 100%, 0-100% H2O in 0.5 min, 100-90% H2O 
in 4.5 min and 90% H2O for 10 min) to obtain nine fractions named CO105-32-1 to 9, 
which were further tested for their anti-protease activity. Fraction CO105-32-9 was active 
against the proteases cathepsins B and L, falcipain-2 and rhodesain. Fraction CO105-32-
9 was subjected to preparative RP HPLC using H2O/MeOH gradient (50-0% H2O in 10 
min, 100% MeOH for 10 min, 0-50% H2O in 2 min, and 50% H2O for 10 min) to obtain 3 
fractions. Further bioactivity testing showed that fraction CO105-32-9-3 inhibited the 
proteases cathepsins B and L, falcipain-2 and rhodesain. The nearly pure bioactive 
compound CO105-32-9-3 was subjected to NMR and MS analysis. 
 
Moreover, the immunomodulatory active fraction CO105-23 obtained as described above 
was partitioned by semi-preparative RP-HPLC using H2O/MeOH gradient (50-0% H2O in 
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14 min, 100% MeOH for 3 min, 0-50% H2O in 8 min and 50% H2O for 2 min) to obtain 
twenty fractions named BA105-23-1 to 20 and further tested for their immunomodulatory 
activity and subjected to LC-MS analysis.  
 
3.3. Bioactivity screening 
3.3.1. Antimicrobial assay – Disk diffusion  
The disk diffusion assay was performed using the following microorganisms: 
Staphylococcus aureus NCTC 8325, Pseudomonas aeruginosa, Enterococcus faecalis 
JH212, Escherichia coli 536 and Candida albicans. 100 L crude extracts (10 mg/mL) 
were added to sterile 13 mm disks three times, and were allowed to dry between each 
addition. Previously prepared LB (for bacterial pathogens) and YPD (for C. albicans) agar 
plates were uniformly inoculated with a lawn of the test bacterial strains on the agar 
surface. The disks were then pressed lightly on the agar surface and incubated at 37 °C 
overnight. Zones of inhibition were noted by measuring the diameter (mm) of the clearing 
zones around the disks. 
 
3.3.2. Antibacterial assay  
Bacterial (Staphylococcus aureus NCTC 8325, Staphylococcus epidermidis RP62A, 
Enterococcus faecalis JH212, Enterococcus faecium 6413, Escherichia coli 536, 
Pseudomonas aeruginosa, Yersinia pseudotuberculosis 252 01A and Yersinia pestis 
KUMA) strains were cultivated overnight at 37 °C (30 °C for Yersinia) in Luria-Bertani 
medium (per liter: 5 g NaCl, 5 g yeast extract and 10 g tryptone) in a shaking incubator. 
The culture was diluted 1:100 in Müller-Hinton broth (23 g per liter; Fluka) the following 
day, and again cultivated until the cells reached the exponential growth phase. 
Approximately 1 x 105 cells/mL were incubated with various concentrations of the 
compounds to make a final volume of 200 L in a 96-well plate at 37 °C for 18 h (at 30 °C 
for 48 h for Yersinia). The final concentration of DMSO was 0.8% in each well. After 
incubation, the optical density of the cultures was determined at 550 nm wavelength 
using an ELISA microplate reader with respect to the control without bacteria or fungi. 
The lowest concentration of the compound at which no bacterial or fungal growth is 
detectable was determined as the minimal inhibitory concentration (MIC). 
 
3.3.3. Biofilm inhibition assay 
Bacterial (Staphylococcus epidermidis RP62A) strain was cultivated overnight at 37 °C in 
in Trypticase-soy-broth (TBS) in a shaking incubator. The culture was diluted 1:200 in 
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TBS and 100 L of bacterial culture were transferred into wells of 96-well plates. 100 L 
of various concentrations of each crude extract were transferred to the test bacteria in the 
96 well-plates (five replicates per compound). Plates were incubated for 24 h at 37 °C 
and 220 rpm. After incubation, the optical density of the cultures was determined at 550 
nm wavelength using an ELISA microplate reader with respect to the control without 
bacteria. The bacterial suspension was carefully removed from the wells and washed 
three times with PBS. The adhering biofilm-forming bacteria in the wells were dried at 60 
˚C and stained with a saturated crystal violet solution for 5 min. Excessive stain was 
removed by extensive washing under running water, and the plate was dried at room 
temperature. The optical density of the cultures was determined at 490 nm wavelength. 
 
3.3.4. Antifungal assay 
A colony of Candida albicans 5314 (ATCC 90028) was re-suspended in 2 mL of 0.9% 
NaCl. Four microliters of this suspension were added to 2 mL of HR medium. This 
medium was prepared by adding 14.67 g HR Medium in 450 mL H2O, followed by the 
addition of 1.0 g NaHCO3 in 50 mL H2O and subsequent incorporation of the following 
solutions: 420 mL of sodium phosphate (35.60 g Na2HPO4.2H2O per liter) and 80 mL of 
potassium dihydrogen phosphate (27.22 g KH2PO4 per liter, pH 7.2). The test compounds 
were diluted in various concentrations in 100 L of medium in a 96-well microplate with 
final DMSO concentration of 0.4%. One hundred microliters of the Candida suspension 
were added to each well, followed by incubation at 37 °C for 48 h. Optical density was 
measured at 530 nm with respect to a control well without cells. The minimal 
concentration of the compound at which no growth is detectable was considered as the 
MIC value. 
 
3.3.5. Antileishmanial assay 
Leishmania major promastigotes were seeded at a cell density of 1 x 107 cells/mL into 96-
well plates in complete medium (RPMI with NaHCO3, 10% FCS, 2 mM glutamine, 10 mM 
Hepes pH 7.2, 100 U/mL penicillin, 50 g/mL gentamicin, 50 M 2-mercaptoethanol) 
without phenol red (200 L), in the absence or presence of different concentrations of the 
sample. These were then incubated for 24 h at 26 °C, 5% CO2, and 95% humidity. 
Following the addition of 20 L of Alamar Blue, the plates were incubated again and the 
optical densities (ODs) measured 24 and 48 h later with a Multiskan Ascent enzyme-
linked immunosorbent assay (ELISA) reader (Thermo Electron Corporation, Dreieich, 
Germany) using a test wavelength of 540 nm and a reference wavelength of 630 nm. 
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Absorbance in the absence of compounds was set at 100% of the growth. Amphotericin B 
was used as a reference compound and positive control. The effects of cell density, 
incubation time and the concentration of DMSO were examined in control experiments. 
The final concentration of DMSO in the medium never exceeded 1% (v/v) and had no 
effect on the proliferation of extracellular or intracellular parasites (Ponte-Sucre et al., 
2006). 
 
3.3.6. Antitrypanosomal assay 
Trypomastigote forms of Trypanosoma brucei brucei laboratory strain TC 221 were 
cultured in Complete Baltz medium (80 mL Baltz Medium Basic Solution, 0.8 mL 2 
mercaptoethanol stock solution (20 mM), 0.8 mL penicillin/streptomycin (10,000 U/mL), 
16 mL FCS (deactivated for 30 min at 56 °C)). Baltz Medium Basic Solution is composed 
of the following: 500 mL MEM with Earle’s salts and L-glutamine, 3 g Hepes, 0.5 g 
monohydrate glucose, 0.110 g sodium pyruvate, 0.007 g hypoxanthine, 0.002 g 
thymidine, 0.0107 g adenosine, 0.0141 g bathocuproine disulfonic acid disodium salt, 
0.146 g glutamine, 5 mL sterile non-essential amino acid concentrate (100x, pH 7.5) 
(Baltz et al., 1985). A defined number of parasites (104 trypanosomes per mL) were 
exposed in test chambers of 96-well plates to various concentrations of the test samples 
(previously dissolved in DMSO) to make a final volume of 200 L in duplicate. Positive 
(trypanosomes in culture medium) and negative controls (test samples without 
trypanosomes) were run simultaneously with each plate. The plates were then incubated 
at 37 °C in an atmosphere of 5% CO2 for a total time period of 72 h. After 24 h, 20 L of 
Alamar Blue was added. The activity of the test samples was measured by light 
absorption using MR 700 microplate reader at a wavelength of 550 nm with a reference 
wave length of 630 nm. The first reading was done at 48 h and subsequently at 72 h. The 
effect of test substances was quantified in IC50 values by linear interpolation of three 
independent measurements (Huber and Koella, 1993, Raz et al., 1997). 
 
3.3.7. Cytotoxicity assays 
J774.1 macrophages were cultured in complete medium (RPMI with NaHCO3, 10% FCS, 
2 mM glutamine, 10 mM Hepes pH 7.2, 100 U/mL penicillin, 50 g/mL gentamicin, 50 M 
2-mercaptoethanol) without phenol red in the absence or presence of different 
concentrations of the samples at a cell density of 1 x 105 cells/mL (200 L) for 24 h at 37 
°C, 5% CO2, and 95% humidity. Following the addition of 20 L of Alamar Blue, the plates 
were incubated and the ODs measured at 24, 48 and 72 h later. The same Alamar blue 
assay as previously described for Leishmania followed. Kidney epithelial 293T cells were 
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also tested in the same manner as the macrophages but using complete DMEM medium 
(4.5 g/L solution of DMEM high glucose solution with sodium pyruvate but without L-
glutamine, FBS superior at final concentration of 20%, 200 mM L-glutamine 100x) and a 
cell density of 2 x 104 cells/mL. 
 
3.3.8. Protease inhibition assays 
Cathepsins B and L and rhodesain protease inhibition assays were performed, according 
to Vicik et al. (2006a, 2006b). Briefly, assays were done at 25 C in a 20 mM Tris-HCl 
buffer pH 6.0 (cathepsins), or in an 50 mM acetate buffer pH 5.5 (rhodesain), with a total 
volume of 200 L. The final substrate concentration was 6.25 and 100.0 M for 
cathepsins B and L and 10.0 M for rhodesain. The final enzyme concentration was 53 
ng/mL for cathepsins B and L, and 41 nM for rhodesain. The falcipain-2 inhibition assay 
was performed as previously described by Breuning et al. (2010). The enzymes were 
incubated with crude extracts for 5 min prior to substrate addition in a total volume of 200 
L. The following buffer was used: 50 mM acetate, pH 5.5 supplemented with 5 mM 1,4-
dithiothreitol (DTT) and 5 mM EDTA. Substrate (Cbz-Phe-Arg-AMC for all four enzymes) 
and inhibitor stock solutions were prepared in 10% final concentration dimethyl sulfoxide 
(DMSO) and were diluted with assay buffer. Crude extracts were tested in duplicate at a 
final concentration of 20 g/mL. Protease inhibition assays were carried out on a Cary 
Eclipse fluorescence spectrophotometer (Varian, Darmstadt, Germany) using a 
microplate reader (excitation 365 nm, emission 460 nm). 
 
The fluorometric SARS-CoV Mpro and Plpro protease inhibition assays were performed 
according to Kaeppler et al. (2005). Briefly, assays were performed at 25 C in a 20 mM 
Tris-HCl buffer pH 7.5 in a total volume of 200 L. The final substrate (H2N-Abz-Ser-Val-
Thr-Leu-Gln-Ser-Gly-(NO2)Tyr-Arg-(MTS)-TFA-salt for Mpro and Z-Arg-Leu-Arg-Gly-Gly-
AMC-acetate salt for Plpro) concentration for inhibition assays was 50 M, and the final 
enzyme concentration was 4.25 g/mL. Crude extracts were tested in duplicate at a final 
concentration of 20 g/mL. Assays were carried out at 325 nm (excitation) and 425 nm 
(emission) for SARS-CoV Mpro and at 365 (excitation) and 425 nm (emission) for SARS-
CoV PLpro.  
 
3.3.9. Immunomodulatory assays 
Peripheral blood mononuclear cells (PBMC) from healthy donors were prepared as a 
byproduct of platelet concentrates obtained with leukoreduction system chambers. The 
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cell concentrate was then diluted in versene (ethylenediaminetetraacetic acid, EDTA). 
PBMCs were isolated from this preparation using density gradient centrifugation with 
Lymphocyte Separation Medium (PAA Laboratories GmbH, Pasching, Austria) and 
washed with ice-cold balanced salt solution (BSS)/0.2% bovine serum albumin (BSA). 
Cells were counted and cultured in Roswell Park Memorial Institute (RPMI) medium 1640 
plus L-glutamine, supplemented with 50 mM mercaptoethanol, MEM non-essential amino 
acids (100X), 1 mM sodium pyruvate (Gibco BRL, Gaithersburg, MD, USA), 100 U/mL 
penicillin (Grünenthal GmbH, Aachen, Germany) and 100 U/mL streptomycin sulfate 
(Riemser Arzeimittel, Greifswald, Germany), 10 mM (2-hydroxyethyl)-1-
piperazineethanesulfonic acid (Hepes) (AppliChem GmbH, Darmstadt, Germany) and 
10% AB-positive heat-deactivated (30 min at 56 °C) human serum (PAA Laboratories 
GmbH, Pasching, Austria). Cells were stimulated in triplicate using 96-well cell culture 
plates (Greiner Bio-One, Kremsmünster, Austria) (2 x 105 cells in 200 L per well) in a 
humidified incubator at 37 °C with 5% CO2. To increase sensitivity of T cells to 
stimulation, PBMC were pre-cultured for 48 hours at 1.5 x 107 cells in 1.5 mL medium in 
24 well plates (Römer et al., 2011). Supernatants were collected after 24 h and stored at -
20 °C. A panel of cytokines (TNF, IFN- , IL-2 and IL-10) was measured by Cytometric 
Bead Array (CBA) (BD Biosciences, San Jose, CA, USA), using an LSR II flow cytometer 
(BD Biosciences, San Jose, CA, USA) following the manufacturer’s instructions. Results 
were analyzed using FCAP Array software (Soft Flow, Inc., USA). Forty-eight hours after 
the stimulation, cell proliferation was measured as radioactivity incorporated into DNA 
from tritiated thymidine during a 24 hour pulse, using a liquid scintillation counter 
(PerkinElmer, Waltham, MA, USA).  
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4. Results 
 
4.1. Bioactivity screening of crude extracts from sponge biomass 
4.1.1. Amphimedon compressa and Aiolochroia crassa 
4.1.1.1. Antimicrobial activity 
Crude methanol, dichloromethane and cyclohexane extracts from the sponges A. 
compressa (Am, Ad and Ah) and A. crassa (Pm, Pd and Ph), as well as the fractions from 
the crude cyclohexane extract (Ah1 - Ah6) from the sponge A. compressa (Figure 19), 
were tested against different bacteria, parasites and fungi, such as Staphylococcus 
aureus, Staphylococcus epidermidis, Enterococcus faecalis, Enterococcus faecium, 
Escherichia coli, Pseudomonas aeruginosa, Yersinia pseudotuberculosis, Yersinia pestis, 
Leishmania major, Trypanosoma brucei brucei and Candida albicans. The cytotoxicity 
was tested by using macrophages and kidney epithelial cells. Only antitrypanosomal 
activity was detected. The following fractions exhibited activity against the parasite 
Trypanosoma brucei brucei (Table 2): cyclohexane sub-fractions Ah2, Ah3 and Ah5, from 
the sponge A. compressa, the crude dichloromethane extract Ad from A. crassa, and the 
methanol crude extracts Am and Pm from the sponges A. crassa and A. compressa.  
 
 
Figure 19. Fractionation of crude extracts from sponges A. compressa and A. 
crassa. Only crude extracts Ah and Am from A. crassa were further fractionated. 
CL: cathepsin L, Fp-2: falcipain-2, Rho: rhodesain and Tbb: Trypanosoma brucei 
brucei. 
 
A. compressa (A)
A. crassa (P)
Lyophilized sponge
material (10 g)
Cyclohexane (h) Dichloromethane (d) Methanol (m) (CL 59%, Fp-2 36%   
and Rho 92%)
1        2        3
45 mg
(CL 97%, Fp-2 
71% and Rho 
98%)
a        b         …. f         g(5 mg. CL 97%, Fp-2 
83%  and Rho 97%, 
IC50 = 11 µg/mL, Rho)
500 mg80 mg
(10 mg. IC50 = 
2.12 µg/ml, Tbb)
1        2     …. 5
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Table 2. Antitrypanosomal activity of crude extracts from sponges A. compressa and A. crassa 
Sponge Code Description 48 h IC50 ( g/mL) 72 h IC50 ( g/mL) 
Amphimedon 
compressa 
Ah crude hexane extract  ND ND 
Ah1 hexane fraction 1 ND ND 
Ah2 hexane fraction 2 16.64 ± 0,42 > 29 ± n.d. 
Ah3 hexane fraction 3 7.29 ± 2,73 > 10 ± n.d. 
Ah4 hexane fraction 4 ND ND 
Ah5 hexane fraction 5 2.12 ± 0,34 2.78 ± 0,09 
Ad crude dichloromethane extract  ND ND 
Am methanol crude extract  6.02 ± 2,27 >10 ± n.d. 
Aiolochroia 
crassa 
Pd dichloromethane crude extract  3.95 ± 1 > 18 ± n.d. 
Pm methanol crude extract 16.73 ± 21.18 > 27± n.d. 
ND: Not detected.  
 
 
4.1.1.2. Anti-protease activity 
Six crude extracts from the sponges A. compressa and A. crassa, six sub-fractions from 
the crude cyclohexane extract and four sub-fractions from the crude methanol extract 
from A. compressa, were tested for their anti-protease activities (Table 3).  
 
Table 3. Protease inhibitory activities of crude extracts from sponge biomass 
Sponge Code  Description  
% Protease inhibition 
Cathepsin 
B 
Cathepsin 
L 
Falcipain
-2 
Rhodesain 
Amphimedon 
compressa 
Ah  crude hexane extract  ND ND 25 ND 
Ad  crude dichloromethane 
extract  
12 24 37 12 
Am crude methanol extract 10 59 36 92 
 Am1 sub-fraction 1 from Am * 97 71 98 
  Am1a Amphitoxin  * 97 83 97 
 Am2 sub-fraction 2 from Am * 91 48 95 
 Am3 sub-fraction 3 from Am * 26 13 21 
Aiolochroia 
crassa 
Ph crude hexane extract  15 ND 20 ND 
 Pd crude dichloromethane 
extract  
17 ND ND ND 
 Pm crude methanol extract  10 20 ND ND 
ND: Not detected. * Since Am did not exhibit activity against cathepsin B, SARS-CoV Mpro and 
SARS-CoV Plpro, the sub-fractions Am1, Am2, Am3 and Am1a were not tested against them. 
Crude extracts and fractions were tested at a final concentration of 20 g/mL. The mean value 
of two assays is shown, standard deviation < 10%. 
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The crude methanol extract of A. compressa effectively inhibited rhodesain and, to a 
lesser degree, cathepsin L and falcipain-2. Am was fractionated using column 
chromatography to obtain three fractions; the first fraction, Am1, was active against 
rhodesain, cathepsin L and falcipain-2. After preparative HPLC analysis of the sub-
fraction Am1, seven sub-fractions (Am1a - Am1g) were collected, and according to LC-
MS analysis, it was noted that the first fraction (Am1a) corresponded to a nearly pure 
compound. 
 
The sub-fraction Am1a from A. compressa exhibited 97% inhibition of the proteases 
cathepsin L and rhodesain, and 71% inhibition of falcipain-2 at 20 g/mL. Am1a showed 
an IC50 value of 11.1 g/mL when tested against rhodesain. Furthermore, antimicrobial 
screening showed that Am1a was active against Yersinia pseudotuberculosis, Yersinia 
pestis, Staphylococcus epidermidis, Enterocococcus faecalis, Enterococcus faecium 
6413, Yersinia pseudotuberculosis, Trypanosoma brucei brucei and Leishmania (Table 
4). The cytotoxicity of sample Am1a was tested using human kidney epithelial cells and 
fibroblast cells, observing that Am1a is toxic to kidney epithelial cells with an IC50 value of 
2,62 g/mL (SI = 0.44). The selectivity index calculated for Trypanosoma brucei brucei 
suggested that Am1a contains a highly toxic compound, which should not be considered 
a drug candidate. 
 
 
Table 4. Antimicrobial activity of fraction Am1a 
 
MIC: Minimum inhibitory concentration, IC50: half maximal inhibitory 
concentration 
 
Organism or cell type Activity 
Antimicrobial activity  
Yersinia pseudotuberculosis MIC: 8 µg/mL 
Yersinia pestis MIC: 2 µg/mL 
Staphylococcus epidermidis RP62A MIC: 8 µg/mL 
Enterocococcus faecalis JH 212 MIC: 8 µg/mL 
Enterococcus faecium 6413 MIC: 8 µg/mL 
Yersinia pseudotuberculosis MIC: 8 µg/mL 
Trypanosoma brucei brucei IC50 (48 h): 6.02 ± 2.27 µg/mL 
Anti-leishmanial activity  
J774.1 Macrophages (Mouse) IC50 : 3.3 µg/mL 
Leishmania major IC50: 3.75 µg/mL 
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The 1H-NMR data suggested that the active compound in Am1a was amphitoxin (Figure 
20), a high molecular weight metabolite, containing 3-alkyl- and 3-alkenyl-pyridinium 
units, previously described in A. compressa (Albrizio et al., 1995, Thompson et al., 2010). 
In this study, NMR data showed signals in the aromatic region at (H) 8.8-8.9, 8.3-8.5 and 
8, which are an evidence of the 3-substituted pyridinium ring in the molecule. The signals 
at (H) 5.59 and 5.70 showed the presence of an olefinic moiety and signals at 2.87, 3.67 
and 4.61 suggested the presence of CH2 groups attached to the pyridine ring (Suppl. Fig. 
S3). The signals between (H) 1.2 and 2.2 evidenced CH2 groups located further away 
from the pyridinium moiety. Sub-fraction Am1a was subsequently analyzed by reversed 
phase LC-MS, only one peak at a retention time of 20 min was observed, detected at 254 
nm (Suppl. Fig. S1). Several ion peaks in the range of 298-3923 m/z were observed, 
confirming the high molecular weight of the compound in Am1a (Suppl. Fig. S2). Based 
on the above observations, it was concluded that the protease inhibitor present in Am1a 
corresponded to amphitoxin. 
 
 
 
Figure 20. Amphitoxin 
 
 
4.1.1.3. Immunomodulatory activity 
Human PBMC were stimulated with crude extracts from the sponges A. compressa (Am) 
and A. crassa (Pm) in the presence and the absence of the T cell activating agent OKT3. 
After 24 h the cytokine concentration was measured in the culture supernatants, and after 
48 hours, cell proliferation was determined by incorporation of tritiated thymidine. The 
crude extracts Am and Pm did not stimulate PBMC proliferation (Figure 21a) while they 
effectively suppressed the PBMC response to the monoclonal antibody OKT3 (Figure 
21b). The fractions Am and Pm at a final concentration of 10 g/mL exhibited 97% and 
45% inhibition of PBMC response to OKT3 respectively. 
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Figure 21. PBMC stimulation with crude extract Pm from the sponge A. crassa in the 
presence (a) and the absence (b) of OKT3. 
 
When PBMC were stimulated with the crude extract Pm, the induction of IL-2, IL-10 and 
TNF cytokines was observed, indicating the proliferative activity of Pm. In the suppression 
experiment, inhibition of IL-2 and IL-10 was not observed; instead, IL-2 and IL-10 
production by PBMC was higher than their production by PBMC in the positive control, 
where cells were stimulated only with OKT3 (Figure 22). This fact again indicates the 
mitogenic activity of the crude methanol extract Pm. Moreover, sample Pm inhibited TNF 
and IFN-  release, suggesting the suppression of the T cell response to OKT3. In 
consequence, extract Pm may contain immunomodulatory metabolite(s). When PBMC 
were stimulated with crude extract Am, no cytokine release or inhibition was observed. 
 
 
Figure 22. Cytokine responses of pre-cultured human PBMC to crude methanol extracts 
from A. crassa (Am) in the presence (a and b) and absence (c and d) of OKT3. Samples 
were tested in triplicate at three different concentrations (25, 2.5 and 0.25 g/mL) 
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4.1.2. Theonella swinhoei 
The sponge T. swinhoei was collected offshore Israel in the Red Sea, and extracts were 
prepared through sequential extraction of the freeze-dried sponge with cyclohexane, 
dichloromethane and methanol (Figure 23). LC-MS analysis of the three preparations 
showed that the crude dichloromethane extract (Td) yielded an ion peak at m/z 670.1 
[M+H]+, which indicated the presence of miraziridine A (Figure 24). The Td extract was 
further partitioned using sephadex HL-20 to obtain three sub-fractions (Td-1, -2, -3) which 
were subsequently analyzed by LC-MS, observing that the sub-fraction Td-3 contained 
the pentapeptide (Suppl. Fig. S4 and S5). When comparing the mass spectra of 
miraziridine A synthesized according to Schaschke (2004), and of Td-3, a molecular ion 
peak at m/z 670.1 [M+H]+ was observed in both the solution of synthetic miraziridine A 
and in the sub-fraction Td-3. Co-elution experiments were pursued observing only one 
peak at a retention time of 16.2 min. Additionally, a fluorometric assay was performed to 
test the cathepsin L inhibition by the crude extract Td-3 at a concentration of 100 g/mL, 
showing 60% inhibition. 
 
 
Figure 23. Fractionation of crude dichloromethane extract from 
sponge T. swinhoei 
 
 
Figure 24. Miraziridine A  
Sponge T. swinhoei
(T)
Lyophilized sponge
Material (7 g)
Cyclohexane
(h)
Dichloromethane 
(d)
Methanol 
(m)
1        2        3
98 mg
(10 mg, CL 60%, 
m/z 670.1 [M+H]+) 
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4.2. Cultivation and identification of bacterial isolates 
4.2.1. Actinomycete and sphingomonad isolates  
Out of 279 strains cultivated from marine sponges, seawater and marine sediments, a 
total of 79 isolates were found to belong to the order Actinomycetales based on their 16S 
rRNA gene sequences. From the Bahamian sponge collection, 21 actinomycete isolates 
were identified. From the sponge collection in Colombia, 136 strains were cultivated and 
classified according to their morphology and restriction fragment patterns. Forty-eight 
strains were differentiated into nine groups. One or two isolates from each group with the 
same restriction fragment patterns were then selected for subsequent sequencing of their 
16S rRNA genes, including the remaining 88 strains that did not match to any group. Five 
groups were found to belong to Microbacterium, Rhodococcus, Micrococcus, 
Curtobacterium, and Citromicrobium genera, one group to Sphingobium, and the 
remaining three to the class Alphaproteobacteria. From the remaining 88 isolates, 29 
isolates were found to belong to the order Actinomycetales and three isolates to the order 
Sphingomonadales (Table 5 and Table 6). 
 
 
Table 5. 16S rRNA gene based phylogenetic affiliation of actinomycete isolates 
Nr 
Isolate 
code 
Source 
Closest relative by BLAST                   
(Accesion number) 
Sequence 
similarity (%) 
Sequence 
length (bp) 
1 BA1 Plakortis sp. Knoellia subterranea AJ294413  98.2 1451 
2 BA2 Aplysina fistularis Knoellia subterranea AJ294413  98.2 1352 
3 BA3 Aplysina fistularis Knoellia subterranea AJ294413 98.1 1490 
4 BA4 Plakortis sp. Knoellia subterranea AJ294413  98.2 1519 
5 BA5 Plakortis sp. Kocuria palustris Y16263 99.5 1509 
6 BA11 Aplysina fistularis Streptomyces thermocarboxydus U94490 99.8 1492 
7 BA17 Scopalina ruetzleri Salinispora arenicola CP000850 99.9 1479 
8 BA18 Scopalina ruetzleri Salinispora tropica AY371895 99.9 1479 
9 BA19 Aplysina fistularis Salinispora arenicola AY371897 99.9 1481 
10 BA21 Aplysina fistularis Nocardioides hwasunensis AM295258 97.7 1485 
11 BA22 Scopalina ruetzleri Agrococcus jenensis X92492 99.3 1488 
12 BA30 Agelas clathrodes Arthrobacter oxidans X83408 98.6 1488 
13 BA32 Aplysina fistularis Nocardioides oleivorans AJ698724  98.2 1479 
14 BA33 Aplysina fistularis Sanguibacter antarticus EF211071  99.3 1490 
15 BA34 Erylus formosus  Arthrobacter oxydans X83408  99.9 1489 
16 BA43 Agelas clathrodes Arthrobacter oxydans X83408  98.7 1489 
17 BA45 Scopalina ruetzleri Microbacterium aurum Y17229 98.6 1487 
18 BA46 Scopalina ruetzleri Microbacterium schleiferi Y17237 98.5 1486 
19 BA47 Scopalina ruetzleri Microbacterium aurum Y17229 98.6 1486 
20 BA51 Ircinia felix Arthrobacter oxydans X83408 98.6 1590 
21 BA53 Scopalina ruetzleri Lapillicoccus jejuensis AM398397 96.3 1498 
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Nr 
Isolate 
code 
Source 
Closest relative by BLAST                   
(Accesion number) 
Sequence 
similarity (%) 
Sequence 
length (bp) 
22 C056 Dragmacidon reticulata  Rhodococcus corynebacterioides X80615 99.5 1304 
23 CO63 Discodermia dissoluta Mycobacterium farcinogenes AY457084  99.4 1406 
24 CO74 Scopalina ruetzleri Micromonospora coxensis AB241455 99.3 1275 
25 CO75 Scopalina ruetzleri Microbacterium trichotecenolyticum EU714362 99.8 1408 
26 CO81 Dragmacidon reticulata Microbacterium lacticum EU714364 98.8 1388 
27 CO84 Aplysina insularis Streptomyces sp. CNR940 PL04 DQ448741 99.7 1391 
28 CO86 Aplysina insularis Saccharopolyspora shandongensis EF104116 100 714 
29 CO93 Marine sediments Micromonospora coxensis AB241455 99.9 1357 
30 CO99 Aplysina insularis Dietzia maris X81920 98.5 1385 
31 CO100 Agelas clathrodes Gordonia terrae X79286 99.5 1416 
32 CO104 Scopalina ruetzleri Microbacterium hominis AB004727 98.0 1301 
33 CO106 Plakinastrella onkodes Microbacterium hominis AB004727 97.8 1387 
34 CO109 Agelas clathrodes Cellulomonas hominis X82598 99.1 1272 
35 CO113 Marine sediments Gordonia nitida AF148947 99.4 1409 
36 CO116 Scopalina ruetzleri Rhodococcus rhodochrous X79288 99.3 1395 
37 CO121 Discodermia dissoluta Microbacterium chocolatum AM181503 99.7 1410 
38 CO128 Plakinastrella onkodes Microbacterium trichotecenolyticum EU714362 99.8 1397 
39 CO129 Scopalina ruetzleri Rhodococcus equi X80613 99.7 1399 
40 CO133 Discodermia dissoluta Gordonia terrae X79286 99.6 1418 
41 CO135 Discodermia dissoluta Mycobacterium vanbaalenii X84977  98.9 1379 
42 CO141 Plakinastrella onkodes Cellulosimicrobium cellulans X83809 99.3 1315 
43 CO143 Natural sea water Citromicrobium bathyomarinum Y16267 98.8 1355 
44 CO146 Plakinastrella onkodes Microbacterium paraoxydans EU714373 99.9 1403 
45 CO147 Discodermia dissoluta Curtobacterium citreum X77436 99.7 1377 
46 CO155 Marine sediments Rhodococcus rhodochrous AB183422 97.4 1361 
47 CO161 Scopalina ruetzleri Micromonospora coxensis AB241455 99.4 1386 
48 CO164 Marine sediments Micromonospora coxensis AB241455  99.3 1372 
49 CO165 Scopalina ruetzleri Micromonospora aurantiaca AJ245712 99.7 1391 
50 CO168 Discodermia dissoluta Gordonia terrae X81922 99.2 1310 
51 CO173 Aplysina insularis Saccharopolyspora shandongensis EF104116  99.6 1392 
52 CO174 Aplysina insularis Streptomyces sp. CNR940 PL04 DQ448741 99.7 1451 
53 CO177 Monanchora arbuscula Mycobacterium mageritense AY457076 99.9 1391 
54 CO178 Aplysina insularis Streptomyces chartreusis 7106043  100 1393 
55 CO181 Discodermia dissoluta Curtobacterium citreum X77436 99.6 1387 
56 CO183 Scopalina ruetzleri Mycobacterium duvalii U94745 99.8 1308 
 
 
Table 6. 16S rRNA gene based phylogenetic affiliation of sphingomonad isolates 
Nr. 
Isolate 
code 
Source 
Closest relative by BLAST Sequence 
similarity 
(%) 
Sequence 
length (bp) (Accession number) 
1 CO58 Dragmacidon reticulata  Sphingomonas mucosissima AM229669 98.4 1363 
2 CO105 Discodermia dissoluta Sphingobium lactosutens EU675846 98.7 1353 
3 CO132 Monanchora arbuscula Sphingobium abikonensis AB021416 98.4 1349 
4 CO180 Natural sea water Sphingobium abikonensis AB021416 98.4 1352 
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Remarkably, four actinomycete strains exhibited less than 98.1% 16S rRNA gene 
sequence similarities to validly described species. These low similarity values suggest 
that the strains belong to novel taxa (Stackebrandt and Ebers, 2006). Phylogenetic 
analysis (Figure 25a) revealed that these strains belong to the order Actinomycetales 
under the following genera: Lapillicoccus, Microbacterium, Rhodococcus and 
Nocardioides.  
 
The highest number of actinomycete isolates was recovered from Scopalina ruetzleri (20 
isolates), followed by Aplysina insularis (12), Discodermia dissoluta (12), Aplysina 
fistularis (7), Dragmacidon reticulata (5), Agelas clathrodes (5), Plakinastrella onkodes 
(4), Ircinia felix (2), Plakortis sp. (3), Monanchora arbuscula (1), Aiolochroia crassa (1) 
and Erylus formosus (1). Actinomycetes were not recovered from the remaining six 
sponges. Additionally, five isolates were recovered from marine sediments and one 
isolate was recovered from natural seawater. 
 
In terms of actinomycete diversity, the 79 cultivated strains are represented by 20 
different genera, namely Microbacterium (21 isolates), Rhodococcus (10), Streptomyces 
(5), Mycobacterium (6), Micromonospora (5), Knoellia (4), Gordonia (4), Curtobacterium 
(4), Arthrobacter (4) Salinispora (3), Saccharopolyspora (2), Nocardioides (2), 
Citromicrobium (2), Sanguibacter (1), Lapillicoccus (1), Kocuria (1), Dietzia (1), 
Cellulosimicrobium (1), Cellulomonas (1), and Agrococcus (1).  
 
From the second sponge collection in Colombia, seven isolates were identified belonging 
to the order Sphingomonadales and the genera Sphingobium and Sphingomonas. One 
isolate belonging to the genus Sphingomonas, as well as two Sphingobium strains were 
recovered from the sponge Dragmacidon reticulata. The remaining 4 sphingomonad 
isolates were found to belong to the genus Sphingobium, two of them were recovered 
from natural sea water and the remaining two from the sponges Monanchora arbuscula 
and Ircinia felix. Nearly complete 16S rRNA gene information is provided for four isolates 
(Table 6). The low 16S rRNA gene sequence similarities (<98.5%) of two of these strains 
also suggest the taxonomic novelty at the species-level (Figure 25b). 
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Figure 25. Neighbor-joining trees of isolates and representative species of the order (a) 
Actinomycetales and (b) Sphingomonadales based on nearly complete 16S rRNA gene 
sequences. Numbers at the nodes indicate the levels of the bootstrap support based on 1,000 
resampled data sets. Only values greater than 50% are shown. The arrow points to the outgroup 
consisting of four species belonging to Methanosarcinaceae. The scale bar indicates 0.05 
substitution per nucleotide position. 
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4.3. Bioactivity screening of crude extracts from bacterial isolates 
4.3.1. Antimicrobial activity  
According to taxonomic novelty and literature reports, 16 isolates were selected for 
bioactivity screening and grown using liquid and solid M1 medium. Broths and crude 
extracts from cultures were tested against gram negative and gram positive bacteria, as 
well as fungi, by performing the disk diffusion bioassay. S. arenicola strain BA17 exhibited 
activity against S. aureus and C. albicans, whereas the isolate M. coxensis strain CO74 
showed an inhibitory effect on S. aureus growth (Table 7). 
 
 
Table 7. Antimicrobial activity of crude extracts from bacterial isolates (disk 
diffusion assay) 
Isolate  Microorganism  
Zone of inhibition 
(mm) 
S. arenicola strain BA17 S. aureus 10 
 
C. albicans 25 
M. coxensis strain CO74 S. aureus 10 
 
 
Furthermore, antimicrobial assays performed in cooperation with the TP Z1 project (SFB 
630), has shown that crude extracts from S. arenicola strain BA17, A. oxydans strain 
BA34 and Lapillicoccus sp. BA53 are bioactive. The isolate S. arenicola strain BA17 was 
active against S. aureus and C. albicans and the M. coxensis strain CO74 was effective 
in inhibiting the growth of S. aureus. In terms of biofilm inhibitory activity, the isolate S. 
arenicola strain BA17 showed 35% biofilm inhibition, and isolates A. oxydans strain BA34 
and Lapillicoccus sp. BA53 showed 30% biofilm inhibition. These results are not relevant; 
nevertheless, the biofilm inhibition observed in the assay is an indicator of a weak 
antibacterial activity. A compound is assumed to possess biofilm inhibiting activity, if sub-
inhibitory concentrations (i.e. below the minimal inhibitory concentration) inhibit the biofilm 
formation without compromising cell growth. 
 
4.3.2. Protease inhibitory activity 
Crude extracts of 16 isolates cultivated in liquid M1 medium and obtained at different 
points in time (4, 7, 14 and 21 days), were tested for their activities against the proteases 
cathepsins B and L, falcipain-2, rhodesain, SARS-CoV PLpro, and SARS-CoV Mpro (Table 
8). Among the crude extracts tested, eight isolates exhibited anti-protease activity. 
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Extracts were considered active when, at a concentration of 20 g/mL, inhibition of at 
least 40% was observed in the assays. The strains Nocardioides sp. BA21, 
Saccharopolyspora shandongensis strain CO86 and Sphingobium sp. CO132 inhibited 
rhodesain. The isolates Agrococcus jenensis strain BA22 and Sphingobium sp. CO180 
inhibited cathepsin B and falcipain-2. Micromonospora coxensis strain CO74 was active 
only against falcipain-2 and Rhodococcus sp. CO155 was active only against cathepsin 
L. Extracts of Micromonospora coxensis strain CO164 were most active, inhibiting all four 
proteases tested. No inhibition of the SARS-CoV proteases was observed, while the rest 
of the crude extracts did not exhibit any protease inhibitory activity. In fluorimetric assays 
the enzyme activity is measured by the hydrolysis rate of a fluorogenic or chromogenic 
substrate (Ludewig et al., 2010). This means that the substrate and inhibitor compete for 
the enzyme’s active site (Ludewig et al., 2010).  
 
 
Table 8. Anti-protease activities of crude extracts from actinomycete and sphingomonad strains 
grown on M1 medium and extracted at different points in time (4 daysA, 7 daysB, 14 daysC and 21 
daysD). Samples were tested in duplicate at a concentration of 20 g/mL 
 
* Putatively novel species; ND: Not detected 
 
 
4.3.3.  Immunomodulatory activity 
When culturing PBMC in the presence of crude extracts (Figure 26), the isolates 
Agrococcus jenensis strain BA22, Arthrobacter oxidans strain BA30 and Arthrobacter 
oxydans strain BA34 were effective in inducing TNF and IL-10 release (Figure 26a and 
d), while strains Lapillicoccus sp. BA53 and Micromonospora coxensis strain CO164 
Strain 
% Protease inhibition 
Cathepsin B Cathepsin L Falcipain-2 Rhodesain 
Actinomycetes     
Nocardioides sp. BA21* ND ND ND 40 ± 1C 
Agrococcus jenensis strain BA22      41 ± 1D ND 44 ± 2A, 40 ± 4C ND 
Micromonospora coxensis strain CO74      ND ND 42 ± 2D ND 
Saccharopolyspora shandongensis strain CO86 ND ND ND 52 ± 1B 
Rhodococcus  sp. CO155*       ND 44 ± 4B ND ND 
Micromonospora coxensis strain CO164 45 ± 3A 43 ± 2B 41 ± 2B 46 ± 3A, 57 ± 5D 
Sphingomonads     
Sphingobium sp. CO132* ND ND ND 53 ± 3B 
Sphingobium sp. CO180* 49 ± 5A ND  45 ± 1B ND  
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induced IFN- , IL-2 and IL-10 (Figure 26b - d). The isolate Saccharopolyspora 
shandongensis strain CO86 effectively induced the release of IL-2 and IL-10 (Figure 26c 
and d) and Sphingobium sp. CO132 induced the release of TNF, IFN- , IL-2 and IL-10 
(Figure 26a - d). The remaining crude extracts from liquid and solid cultures from bacterial 
isolates did not induce cytokine release in PBMC culture supernatants.  
 
 
Figure 26. Cytokine responses of pre-cultured human peripheral blood mononuclear cells to 
crude extracts from bacterial isolates. a. TNF b. IFN- , c. IL-2 and d. IL-10 Crude extracts 
were tested in triplicate at 3 different concentrations (preparations from liquid cultures: 25 
g/mL, 2.5 g/mL and 0.25 g/mL, from solid cultures: 10 g/mL, 1 g/mL and 0.1 g/mL) 
and the most active one is shown (25 g/mL) 
 
 
With regard to the induction of proliferation, the crude extract prepared from the solid 
culture of strain Sphingobium sp. CO105, exhibited the strongest mitogenic activity, 
reaching 14% of the positive control (OKT3, activating all T cells) (Figure 27). When the 
strain Sphingobium sp. CO105 was tested for its capacity to induce cytokine release, a 
weak induction of IL-2 was observed. The remainder of the samples did not stimulate 
PBMC proliferation.  
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Figure 27. PBMC proliferation in response to stimulation with the 
crude extract from strain Sphingobium sp. CO105. The crude extract 
was tested in triplicate at a concentration of 65 ng/mL 
 
 
4.3.4. Secondary metabolites from bioactive strains Lapillicoccus sp. BA53 and 
Sphingobium sp. CO105 
4.3.4.1. Strain Sphingobium sp. CO105 
Compound CO105-32-9-3. Bioactivity-guided fractionation of the active crude extract 
obtained from the putatively novel sphingomonad isolate Sphingobium sp. CO105 (Figure 
28), yielded 1.5 mg of one nearly pure bioactive metabolite. The compound named 
CO105-32-9-3 was found to inhibit the proteases cathepsins B and L, falcipain-2 and 
rhodesain (Table 9).  
 
 
Figure 28. Bioactivity-guided fractionation of strain Sphingobium sp. CO105. Samples 
were tested in duplicate at a concentration of 20 g/mL 
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Table 9. Anti-protease activities of compound 105-32-9-3 isolated from the actinomycete isolate 
Sphingobium sp. CO105. Sample was tested in duplicate at a concentration of 20 g/mL 
Sample  
% Protease inhibition 
Cathepsin B Cathepsin L Falcipain-2 Rhodesain 
Sphingobium sp. CO105     
Compound 105-32-9-3 59 ± 5 58 ± 7 50 ± 8 54 ± 5  
 
 
The high resolution mass spectrum of compound 105-32-9-3 indicated the molecular 
formula C12H10N4O2 (Rt = 2.02 min, m/z 243.088 [M+H]+). The 1H-NMR spectrum of 
CO105-32-9-3 showed signals in the aromatic region at (H) 7.9 and 7.7 ppm and in the 
high field region at (H) 2.52 and 2.54 ppm. The COSY spectrum of CO105-32-9-3 
showed a correlation between the proton at (H) 7.9 and the proton at (H) 2.52, as well 
as a correlation between the proton at (H) 7.7 and the proton at (H) 2.54. The 
comparison of the NMR and MS spectral data with the MarinLit database revealed that 
the compound CO105-32-9-3 corresponded to the known metabolite isolumichrome 
(Figure 29) (Li et al., 2004). 
 
 
 
Figure 29. Isolumichrome isolated from the solid culture of strain 
Sphingobium sp. CO105. The 1H chemical shifts (ppm) of protons and 
COSY correlations are shown 
 
 
Compound CO105-23-11. When sub-fractions from strain Sphingobium sp. CO105 were 
tested for their immunomodulatory activity, sample CO105-23-11 was effective in 
inducing the release of TNF and, to a lesser degree, IL-10 cytokines (Figure 30). 
Chromatographic profile of CO105-23-11 showed this sample as a nearly pure compound 
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and ESI-MS analysis showed an ion peak at 2.4 min, m/z 511.2 [M+H]+ (Figure 31a and 
b). The chemical structure of the immunomodulatory compound contained in fraction 
CO105-23-11 has yet to be elucidated. 
 
 
 
Figure 30. Cytokine responses of pre-cultured human peripheral blood mononuclear cells to the 
nearly pure compound CO105-23-11. a. TNF b. IL-10. The sample CO105-23-11 was tested in 
triplicate at 25 g/mL 
 
 
a  
 
 
 
 
 
 
 
 
 
b 
 
Figure 31. LC-MS profile of compound CO105-23-11. a. Total ion current (TIC) chromatogram. b. 
ESI-MS spectrum of the peak eluting at 2.4 min 
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4.3.4.2. Strain Lapillicoccus sp. BA53  
Solid culture. Bioactivity-guided fractionation of the active crude extract obtained from 
the solid culture of the putatively novel acinomycete Lapillicoccus sp. BA53, yielded one 
nearly pure bioactive metabolite (Figure 32). The strain Lapillicoccus sp. BA53 was found 
to produce a metabolite named BA53H2-12, which inhibited the proteases cathepsins B 
and L, falcipain-2 and rhodesain (Table 10). 
 
 
 
Figure 32. Bioactivity-guided fractionation of crude extract from solid 
culture of Lapillicoccus sp. BA53. Samples were tested in duplicate at 
a concentration of 20 g/mL 
 
Table 10. Anti-protease activities of compound isolated from the actinomycete isolate Lapillicoccus 
sp. BA53. The sample was tested in duplicate at a concentration of 20 g/mL 
Sample  
% Protease inhibition 
Cathepsin B Cathepsin L Falcipain-2 Rhodesain 
Lapillicoccus sp. BA53     
Compound BA53H2-12 74 ± 2 77 ± 2  91 ± 3 78 ± 2 
 
 
1                2
Lapillicoccus sp. BA53
644 mg  
(CL 45% , Fp-2 
60% and Rho 50%
HPLC (RP-18)
1        2        3       ….       12             ...14
50 mg
A …                H                      …   K
(1.50 mg, CB 74%, CL 77%, 
Fp-2 91% and Rho 98%)
 65 
 
The molecular formula for compound BA53H2-12 was established using high-resolution 
mass spectrometry as C8H9NO3 (Rt = 3.18 min, m/z 268.067 [M+H]+). The combination of 
NMR and MS data, and comparison of the spectral data with the MarinLit database 
(2010), showed that the protease inhibitor isolated from the strain Lapillicoccus sp. BA53 
is the previously reported compound p-aminosalicylic acid methyl ester (Celmer et al., 
1979) (Figure 33).  
 
 
 
Figure 33. Compound BA53H2-12. p-Aminosalicylic acid methyl ester 
isolated from the solid culture of strain Lapillicoccus sp. BA53 
 
 
Liquid culture. The crude extract obtained from the liquid culture of the isolate 
Lapillicoccus sp. BA53, was fractionated in several steps by RP HPLC (Figure 34). The 
six sub-fractions thus obtained (53L30-7, 53L30-9, 53L33-2, 53L34-5, 53L36-6 and 
53L37-7, around 2 mg from each fraction) were tested for their protease inhibitory activity. 
Fractions from liquid culture of strain BA53 did not exhibit protease inhibitory activity. 
 
 
 
Figure 34. Fractionation of crude extract from the liquid culture 
of strain Lapillicoccus sp. BA53 
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The molecular formulas for eleven compounds contained in the six fractions obtained 
from strain Lapillicoccus sp. BA53 were established using high-resolution mass 
spectrometry as follows (Suppl. Fig. 6 and 7): 53L30-7 = C14H16N2O2 (Rt = 1.87 min, m/z 
245.129 [M+H]+); 53L30-9a = C13H16N2O3 (Rt = 2.11 min, m/z 249.122 [M+H]+); 53L30-9b 
= C25H17N3 (Rt = 3.12 min, m/z 360.150 [M+H]+); 53L33-2a = C9H7NO (Rt = 1.28 min, m/z 
146.060 [M+H]+); 53L33-2b = C17H26N4O3 (Rt = 1.37, m/z 335.208 [M+H]+); 53L33-2c = 
C11H12N2O (Rt = 1.98 min, m/z 189.103 [M+H]+); 53L34-5 = C16H24N4O3 (Rt = 3.26 min, 
m/z 321.197 [M+H]+), 53L36-6 = C21H26N2 (Rt = 3.65, m/z 307.218 [M+H]+), 53L37-7a = 
C16H35NO2 (Rt =1.85, m/z 189.109 [M-H]-), 53L37-7b = C14H18N2O2 (Rt = 2.07, m/z 
247.145 [M+H]+) and 53L37-7c = C9H18O4 (Rt = 3.87, m/z 274.275 [M+H]+). 
 
Furthermore, the combination of NMR (1D and 2D) and comparison of the spectral data 
with the MarinLit database showed that six of the eleven compounds, were previously 
reported from marine sources (Table 11). The stereo-chemical properties of these 
compounds were not determined. The molecular formulas of the compounds 53L33-2b, 
53L36-6, 53L37-7a and 53L37-7b did not have any matches in the MarinLit database, 
suggesting that these compounds may be novel secondary metabolites.  
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   Table 11. Secondary metabolites identified in the actinomycete strain Lapillicoccus sp. BA53 
Sample Identified compound Name Reference Source 
53L30-7 
 
C14H16N2O2, MW: 244.29 
Benzyldiketopiperazine 
Debitus  et al. 1998 J. 
Mar. Biotechnol 6(3), 
136-141 
Arctic ice bacterium, marine 
Pseudomonas sp. from sponge Suberea 
creba and the fungi Tyridiomyces 
formicarum 
53L30-9a 
 
C13H16N2O3, MW: 248.278 
SA4-3 
Tanaka et al., 1987 Jpn. 
Kokai, Tokkyo Koho JP, 
Appl. 86/27,437 
Streptomyces actamyceticus ms4-3 
 
53L30-9b 
 
C25H17N3, MW: 359.423 
Bis(3-indolyl)-3H-
indolylidenmethan 
 
Budzikiewicz H. et al. 
1972 Tetrahedron Lett. 
36, 3807-3810 
Saccharomyces cerevisiae 
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53L33-2a 
 
C9H7NO, MW: 145.158 
Indole-3-carbaldehyde 
Palermo et al. (1992) 
Tetrahedron Lett., 33, 
3097-100 
Red alga Chondria sp.; marine 
Alteromonas luteoviolaceum, marine 
Janibacter limosus, bacterium Bio232 
53L34-5 
 
C16H24N4O3, MW: 320.387 
Arphamenine A Umezawa et al. 1984 J. Antibiot. 36, 1572- 1575 
Chromobacterium violaceum bmg 361-
cf4  
53L37-7 
 
C14H18N2O2, MW: 246,305 
Cyclo(L-Val-L-Phe) 
Pickenhagen et al. 1975 
Helv. Chim. Acta 58, 
1078-86 
Cocoa 
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5. Discussion 
 
5.1. Secondary metabolites from the sponges Amphimedon compressa, 
Aiolochroia crassa and Theonella swinhoei 
Marine sponges have been proven to be a rich source of secondary metabolites 
exhibiting a huge diversity of biological activities, including antimicrobial, antitumor and 
immunomodulatory activities. The motivation to investigate the potential of sponges 
Amphimedon compressa, Aiolochroia crassa and Theonella swinhoei as producers of 
bioactive secondary metabolites was based on a previous study were a group of 18 
species of marine sponges were tested for their protease inhibitory activities. Among the 
investigated sponges, crude extracts from Amphimedon compressa, Aiolochroia crassa 
and Theonella swinhoei showed the highest biological potential. This fact, added to the 
few reports of protease inhibitors from marine organisms (see introduction), indicated that 
searching for protease inhibitors in these three marine sponges is an interesting approach 
to explore.  
 
Furthermore, marine-derived secondary metabolites have inspired the development of 
many drugs currently in use for the treatments of a broad number of human diseases. A 
good example is the agelasphin 9b story. This sponge-derived immunomodulator has 
served as an inspiration compound to synthesize KRN7000 ( GalCer) (Natori et al., 
1993). KRN7000 has been shown to be a potent NKT cell stimulator, and has been used 
to combat cancer, inflammation and infection (Godfrey and Kronenberg, 2004). Additional 
work has shown that GalCer exhibits adjuvant properties that can be used for vaccine 
development (Fujii et al., 2003). The low solubility of GalCer in water has complicated 
the in vivo applications to evaluate its potential as immunomodulator. In 2007, 
galcelMPEG has been synthesized by Ebensen et al., which is a derivative of the 
substance KRN7000 and has shown to have improved immunomodulatory properties at a 
lower concentration. Synthetic GalCerMPEG exhibited in vitro stimulatory properties on 
immune cells, such as dendritic cells and splenocytes and strong adjuvant properties in 
vivo, which makes it suitable for use in vaccination (Ebensen et al., 2007). This is one 
example of what nature offers us; and one of my motivations to investigate marine 
environments, as laid out in this PhD thesis.  
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Theonella swinhoei 
This study showed that the sponge T. swinhoei from the Red Sea represents an 
alternative source of the aziridinylpeptide miraziridine A to the previously identified T. 
mirabilis from Japan (Tabares et al., 2011a). Moreover, the results here presented 
confirmed that miraziridine A is produced by marine sponges from different geographic 
locations. Theonella species (order Lithistida, Demospongiae) have been shown to be a 
source of several bioactive secondary metabolites. Theonella swinhoei has been studied 
by Piel et al. (2005) for being associated to several microbial symbionts, which are 
suggested to be the true producers of many secondary metabolites. T. swinhoei has been 
reported for producing the antitumor polyketides onnamides and theopederins (Sakemi et 
al., 1988, Fusetani et al., 1992). In 2004 the antitumor polyketide biosynthesis by a 
bacterial symbiont of T. swinhoei was reported by Piel et al. In this study, miraziridine A 
was identified in the dichloromethane extract of the sponge T. swinhoei collected offshore 
Israel in the Red Sea. Miraziridine A, a natural peptide isolated previously from the 
marine sponge Theonella aff. mirabilis, is a potent cathepsin B inhibitor with an IC50 value 
of 2.1 M (Nakao et al., 2000).  
 
Miraziridine A has already served as a model for synthetizing protease inhibitors (Konno 
et al., 2007). Interestingly, protease inhibitors have been reported from microbial sources, 
as well; for example, (2S,3S)-aziridine-2,3-dicarboxylic acid (Naganawa et al., 1975) and 
leupeptin (Hozumi et al., 1972) have been reported from actinomycete strains, and 
circinamide from cyanobacteria isolates (Shin et al., 1997). (2S,3S)-Aziridine-2,3-
dicarboxylic acid and circinamide contain an aziridine moiety, to which also the inhibitory 
activity of miraziridine A is mainly attributed (Konno et al., 2007). Moreover, the 
actinomycete Kibdelosporangium sp. was found to produce the aziridine-containing 
metabolite azinomycin A (Ogasawara and Liu, 2009). Actinomycetes and cyanobacteria 
constitute part of the microbial consortia present in marine sponges that can account for 
nearly half of the sponge’s biomass (Hentschel et al., 2006, Taylor et al., 2007). This fact 
suggests that protease inhibitors such as miraziridine A can be the result of the symbiotic 
interactions between microbes and sponge. 
 
Furthermore, protozoa, e.g. plasmodia, express a broad spectrum of proteases essential 
for the survival of the parasite (Breuning et al., 2010) and it is known that cysteine and 
aspartic acid protease inhibitors are synergistic against plasmodia (Semenov et al., 
1998). It will be interesting to re-synthesize miraziridine A and perform further bioactivity 
testing in the future, where miraziridine A would be tested alone or in combination with 
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aspartic acid inhibitors. It will also be of scientific interest to synthesize miraziridine A-
derived molecules. For instance, the shortening of the molecule by combining only two of 
the three protease-inhibiting building blocks (aziridine and statine, aziridine and 
vinylogous arginine, or vinylogous arginine and statine) will represent an alternative to 
produce potent protease inhibitors.  
 
Amphimedon compressa 
In this study, amphitoxin was isolated from the sponge Amphimedon compressa (order 
Haplosclerida) and was shown for the first time to have protease inhibitory activities. 
Alkylpyridinium compounds from marine sponges have also shown cytotoxic, 
ichthyotoxic, antibacterial, enzyme-inhibitory and anti-fouling properties (Jeanteur et al., 
2006, Albrizio et al., 1995). The reports about the toxicity of amphitoxin in the respective 
literature, and the cytotoxicity analysis here presented, have shown amphitoxin to be a 
potent toxic agent. This fact leads me to consider the usefulness of amphitoxin and 
alkylpyridinium salts as materials with biotechnological potential instead of as an 
alternative for therapeutic agents for the treatment of human diseases. Several 
alkylpyridinium salts derived from sponges of the order Haplosclerida have been shown 
to have anti-fouling properties (Jeanteur et al., 2006). According to the previous 
observations, I consider it important to evaluate the potential of amphitoxin for developing 
anti-fouling paints for ships and offshore constructions, to prevent the growth of 
barnacles, algae, and marine organisms. 
 
Aiolochroia crassa 
The crude extracts from the sponge A. crassa exhibited antitrypanosomal and 
immunomodulatory activities. Few reports of secondary metabolites from the sponge A. 
crassa (order Verongida) have been found e.g. aerophobins, purealidin L and isofistularin 
(Assmann et al., 1998) (see introduction). A. crassa is considered to be a sponge with 
high microbial abundance (Weisz et al., 2008); consequently, a higher diversity of 
bioactive metabolites from this sponge might have to be expected in the literature. The 
order Verongida is well known for producing bromotyrosine-derived alkaloids, which have 
shown biological properties (Ciminiello et al., 1994, Gao et al., 1999). Considering the few 
reports of secondary metabolites from the sponge A. crassa as well as the bioactivities of 
its crude extracts here presented, I consider it interesting in future investigations to 
search for novel and bioactive brominated alkaloids, in this sponge species. Additionally, 
further bioactivity-guided fractionation of the active crude extracts from A. crassa which 
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was beyond the scope of this PhD thesis should be carried out in order to complete the 
elucidation of the structure of the bioactive metabolite(s).  
 
5.2. Isolation and identification of sponge-associated actinomycetes and 
sphingomonads 
Isolates from the order Actinomycetales 
The class Actinobacteria, belonging to the order Actinomycetales, represent Gram-
positive bacteria that are diverse with respect to morphology and biochemistry, as well as 
G+C-rich DNA content. According to Zhi et al. (2009), 219 genera (classified in 48 
families) have been so far accommodated in the class Actinobacteria. In this study, four 
actinomycete isolates were shown to be putatively novel species. While the phenotypic 
and genotypic characterization of novel isolates were not the major aim of this project, it 
is, however, worthwhile to pursue them in further research. 
 
79 actinomycete isolates, represented by 20 genera, were cultivated from 18 different 
species of Caribbean marine sponges (Tabares et al., 2011b). To date this is the only 
report where such a number of species have been studied for cultivation of 
Actinobacteria. Webster et al. (2001) studied the phylogenetic diversity of bacteria 
associated with the sponge Rhopaloeides odorabile where the importance of using 
different media and culture conditions for the cultivation of actinomycetes was shown. 
Zhang et al. (2006) published the cultivation of 106 actinomycete strains from the sponge 
Hymeniacidon perlevis belonging to seven genera. Zhang et al. (2008a) made a 
comparative study on the actinomycete diversity in five marine sponge species from the 
yellow sea in China where a total of 181 actinobacterial strains belonging to seven genera 
were cultivated. More recently, Abdelmohsen et al. (2010) reported the phylogenetic 
characterization of 90 actinomycetes that were isolated from 11 different species of 
marine sponges from offshore Ras Mohamed (Egypt) and from Rovinj (Croatia). In 
addition, among the six cultivation media used to isolate actinomycetes in this project, M1 
and oligotropic media exhibited the highest recovery of isolates. M1 medium has been 
previously reported to be an effective cultivation medium for isolation of actinomycetes. 
Nevertheless, the use of different media as well as different shaking and temperature 
conditions might lead to an increase in the number of rare and novel actinomycete 
bacteria. The cultivation of novel actinomycete strains represents a good strategy for 
isolation of new secondary metabolites with novel skeletons and reduces the efforts of re-
isolating known compounds.  
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The highest number of actinomycete isolates was recovered from the sponge Scopalina 
ruetzleri including the novel and obligate marine strain Lapillicoccus sp. BA53. No reports 
of secondary metabolites from the sponge Scopalina ruetzleri were found in the literature. 
These results showed Scopalina ruetzleri as a significant source of actinomycetes, and 
as such, is presumably also a source of bioactive secondary metabolites. It will be 
interesting in future studies, to search for novel and rare actinomycete isolates in the 
sponge Scopalina ruetzleri, and the use of different cultivation approaches in doing so is 
highly recommended.  
 
Several recent publications have shown that Streptomyces, Micromonospora, and 
Rhodococcus are among the dominant genera commonly isolated from marine sponges 
(Abdelmohsen et al. 2010; Schneemann et al. 2010; Sun et al. 2010; Zhang et al. 2008). 
The actinomycetes isolated in this study displayed considerable diversity; Microbacterium 
(27%) was the most dominant strain followed by Rhodococcus (12%) and Streptomyces 
(9%). Nevertheless, this study also disclosed the isolation of rare Actinobacteria genera, 
namely Cellulosimicrobium, Citromicrobium, Sanguibacter, and Lapillicoccus. 
Furthermore, this is the first report on the cultivation of the genera Citromicrobium, 
Sanguibacter, and Lapillicoccus from marine sponges and of the genus Lapillicoccus from 
the marine environment in general. Interestingly, the strain Lapillicoccus sp. BA53 was 
found to be an obligate marine actinomycete. This is also the first report on the isolation 
of actinomycetes from the sponges Agelas cerebrum, Agelas tubulata, Amphimedon 
compressa, Aplysina archeri, Biemna cribaria and Chondrilla nucula. Based on 16S rRNA 
phylogenetic analyses of actinomycete strains as part of this study, 4 out of the 79 
identified isolates are new actinomycete species belonging to the genera Lapillicoccus, 
Microbacterium, Nocardioides and Rhodococcus.  
 
The strain Lapillicoccus sp. BA53, showed a strict requirement for salt and is the first 
obligate marine bacterium of the genus Lapillicoccus. The genus Lapillicoccus was first 
described by Lee and Lee (2007), reporting the isolation of the species Lapillicoccus 
jejuensis from a small stone collected in Jeju, in the Republic of Korea. Lapillicoccus 
belongs to the family Intrasporangiaceae (Lee and Lee, 2007), which contains 19 genera 
with validly published names. Moreover, strain Lapillicoccus sp. BA53 is of special 
interest due to its protease and immunomodulatory properties. The use of different 
cultivation and extraction techniques might lead to the isolation of novel and bioactive 
compounds from the novel Lapillicoccus species here presented.  
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The genus Microbacterium belonging to the family Microbacteriaceae was the dominant 
genus of this study. The Microbacteriaceae family accommodates Gram-positive bacteria 
with high content of G+C DNA and with the group-B-type peptidoglycan (Park et al., 
1993). Around 73 species have validly published names, including the marine-derived 
species M. flavum, M. lacus, M. marinilacus and M. sediminicola. With regard to the 
production of bioactive secondary metabolites from the genus Microbacterium, four 
glycoglycerolipids from a marine sponge-associated Microbacterium species have been 
reported by Wicke et al. (2000); these showed surfactant properties and antitumor 
activity. 
 
The genus Rhodococcus, belonging to the Nocardiaceae family, has shown a broad 
catabolic diversity and array of unique enzymatic capabilities, and has gained interest 
from scientific researchers in the last decades due to its commercial potential (Bell et al., 
1998, van der Geize and Dijkhuizen, 2004). For example, species of the genus 
Rhodococcus are able to degrade hydrophobic natural compounds and xenobiotics, such 
as polychlorinated biphenyls (PCBs). They have, moreover, been shown as good 
candidates for the industrial production of steroid compounds with pharmacological 
potential (Fernandes et al., 2003, van der Geize and Dijkhuizen, 2004). According to the 
MarinLit database, around 29 secondary metabolites have been isolated from the genus 
Rhodococcus. Considering the interesting background of the genus Rhodococcus, it 
could be worthwhile to use different approaches to produce bioactive and novel 
secondary metabolites from the novel strain Rhodococcus sp. CO155. For example, the 
cultivation of the novel strain Rhodococcus sp. CO155 under different conditions as well 
as the preparation of crude extracts using different extraction methods might increase the 
likelihood of obtaining novel chemical entities.  
 
Isolates from the order Sphingomonadales 
Sphingomonads are of potential importance in the ecology of a range of marine habitats 
(Cavicchioli et al., 1999); they can act as coral pathogens (Richardson et al., 1998), hosts 
for temperate phage (Jiang et al., 1998) and hydrocarbon degraders (Gilewicz et al., 
1997). Sphingomonads are also well known for their biotechnological applications in the 
degradation, bioremediation and wastewater treatment of xenobiotic pollutants 
(Fredrickson et al., 1995, Zipper et al., 1996), and also for their biosynthetic production of 
extracellular polymers (Denner et al., 2001). Seven isolates were found to belong to the 
order Sphingomonadales in this PhD thesis, and four of them represent putatively novel 
species (three Sphingomonas and one Sphingobium). This is the first report on the 
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cultivation of the genus Sphingobium from the marine environment in general. The 
pharmacological activities of sphingomonad isolates were also tested as part of this 
study, which will be discussed in the following sections; however, the evaluation of the 
biotechnological potential of sphingomonad isolates was not included in this project’s 
aims. It would therefore be interesting to evaluate the role of the new strains shown here 
as pollutant degraders, but also as a source of polymers with industrial potential. 
Moreover, further phenotypic and genotypic characterization is required to confirm the 
taxonomic affiliation of these strains.  
 
5.3. Bioactivity screening of sponge-derived actinomycetes and sphingomonads  
Protease inhibitory activity 
The protease inhibitory assays here described involved a fluorometric enzymatic assay. 
This is an effective and rapid method to pursue the identification of enzyme inhibitory 
substances, and is therefore useful to determine kinetic data of protease inhibitors 
(Birdsall et al., 1983, Turk, 2006, Ludewig et al., 2010). The crude extracts of sixteen 
isolates cultivated in M1 medium and extracted at four different points in time were tested 
for their anti-protease activities. This involved testing against the human cysteine 
proteases, cathepsin B and L, and against parasitic proteases falcipain-2 (Plasmodium 
falciparum) and rhodesain (Trypanosoma brucei rhodesiense). Cathepsins B and L are 
proteases ubiquitously expressed in human tissues; they play a role in a large number of 
important physiological processes in the organism, including MHC-II-mediated antigen 
presentation, bone remodeling and keratinocyte differentiation (Turk et al., 2011, Turk et 
al., 2002, Vasiljeva et al., 2007). Furthermore, cathepsins B and L are involved in tumor 
progression and invasion either by direct degradation of the extracellular matrix or by 
activation of other proteases, such as the urokinase-type plasminogen activator (Turk et 
al., 2000). Falcipain-2 is a protease essential to the nutrition of the Plasmodium 
falciparum (malaria), which hydrolyzes erythrocyte hemoglobin in an acidic food vacuole 
to provide amino acids for parasite protein synthesis (Rosenthal et al., 1988). Rhodesain 
is involved in the degradation of parasitic proteins as well as in intracellularly transported 
host proteins in both the insect and the mammalian host (Caffrey et al., 2001). 
Additionally, crude extracts were tested for their capacity to inhibit the papain-like (SARS-
CoV PLpro), and the main protease (SARS-CoV Mpro) of the SARS coronavirus. These 
enzymes are essential for the replication of the severe acute respiratory syndrome 
(SARS) coronavirus (Anand et al., 2003, Ratia et al., 2006). Cathepsin B and L, 
rhodesain and falcipain-2 enzymes belong to the cathepsin L subfamily of cysteine 
proteases (clan CA, family C1; CAC1). SARS-CoV PLpro also belongs to the clan of 
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cysteine proteases CA, but is affiliated with the family C16, which contains polyprotein 
endopeptidases from coronaviruses. The protease SARS-CoV Mpro belongs to the clan 
PA (family 30) with a catalytic type of mixed cysteine, serine and threonine (Rawlings et 
al., 2010).  
 
The crude extracts of eight isolates showed certain specificity to the clan CA (family C1; 
CAC1) group of proteases, whereas no protease inhibition was observed against viral 
proteases. Six actinomycete and two sphingomonad isolates are shown as potential 
sources of protease inhibitors. The inhibition of rhodesain, to which the substrate has a 
particularly high affinity, by extracts of Nocardioides sp. BA21, Saccharopolyspora 
shandongensis CO86, Micromonospora coxensis strain CO164 and Sphingobium sp. 
CO132 is, thus remarkable. Interestingly, the putatively novel strains Nocardioides sp. 
BA21, Sphingobium sp. CO132 and Rhodococcus sp. CO155 exhibited protease 
inhibitory acivity. According to previous reports novel actinomycete species will produce 
novel bioactive secondary metabolites (Pimentel-Elardo et al., 2008, Pimentel-Elardo et 
al., 2011, Kwon et al., 2006). Only few reports of actinomycete-derived protease inhibitors 
were found in the literature (see introduction). These results suggest that marine 
actinomycetes might be a potential source of protease inhibitors, offering a more 
productive route to the discovery of bioactive secondary metabolites.  
 
Immunomodulatory activity 
The protocol employed in this project for evaluating the PBMC response to sponge and 
bacteria-derived substances involved a new methodology developed by Römer et al 
(2011). This protocol includes the stimulation of high cell density pre-cultured PBMC 
instead of freshly prepared PBMC, in order to resemble the environment to which T cells 
are subjected in the lymph nodes, and thus become more reactive; providing a more 
reliable screening method for finding immunomodulatory agents. Römer et al. (2011) 
showed that freshly isolated PBMC fail to respond to the monoclonal antibody (mAb) 
TGN1412, which led to a massive cytokine storm in humans (Suntharalingam et al., 2006, 
Hünig, 2007). Stimulation of PBMC, after two days of pre-culturing at a 10-fold higher cell 
density than usually utilized for in vitro assays resulted in an increase of the response to 
the CD28 superagonist TGN1412, which is comparable to the T cell activating mAb OKT3 
Römer et al. (2011). Moreover, responses to other T cell activating agents such as 
Staphylococcus enterotoxin B (SEB) and a combined tetanus/diphteria toxoid preparation 
were also enhanced when PBMC were pre-cultured for two days before stimulation 
(Römer et al., 2011).  
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When culturing PBMC in the presence of crude extracts, different patterns of cytokine 
release were observed. Even though this assay does not distinguish which cells are 
responsible for cytokine production, some assumptions can be made about their cellular 
source. This is facilitated by the fact that individual extracts induced rather distinct 
patterns of cytokine release. For example, Agrococcus jenensis strain BA22 was very 
active in inducing TNF and IL-10, suggesting that this preparation addresses monocytes. 
In contrast, Micromonospora coxensis strain CO164 was a potent inducer of IFN- , IL-2, 
and, to a lesser extent, IL-10. Since the main source of IFN-  are TH1 CD4+ T cells and 
CD8+ T cells, this preparation appears to have T cell activating properties. Furthermore, 
the induction of IL-2 but not of IFN-  by Saccharopolyspora shandongensis strain CO86 
suggests a further specificity for CD4+ T cell activation. Isolates Agrococcus jenensis 
strain BA22, Arthrobacter oxidans strain BA30 and Arthrobacter oxydans strain BA34 
were effective in inducing TNF and IL-10 release, cytokines induced mainly by monocytes 
and T cells (TNF: TH1, IL-10: TH2 and T reg). Strains Lapillicoccus sp. BA53 and 
Micromonospora coxensis strain CO164 induced IFN- , IL-2 and IL-10. IFN-  and IL-2 
can be released by T helper 1 cells and IL-10 by T helper 2 and regulatory T cells as well 
as monocytes. Saccharopolyspora shandongensis strain CO86 effectively induced the 
release of IL-2 and IL-10. IL-2 is mainly released by TH1 cells and IL-10 is mostly 
produced by macrophages and T helper 2 and regulatory T cells. Sphingobium sp. 
CO132 induced the release of TNF, IFN- , IL-2 and IL-10, indicating a stimulatory effect 
on both T cells and monocytes.  
 
PBMC contain monocytes and lymphocytes, the latter consisting of B cells, T cells (CD4+ 
T cells, CD8+ T cells, and regulatory T cells), as well as NKT cells. Cytokines are proteins 
which are secreted by the cells of innate and adaptive immunity, and which are involved 
in many cellular functions. In the present study, the following cytokines were analyzed 
which are key pro- and anti-inflammatory factors and which are characteristic of particular 
types of immune responses to pathogens: TNF, the principal mediator of the acute 
inflammatory response to Gram-negative infectious microbes, is responsible for many of 
the systemic complications of severe infections. IFN-  is the principal macrophage-
activating cytokine and serves critical functions in innate and in adaptive cell-mediated 
immunity. IL-2 is a cytokine responsible for T cell clonal expansion after antigen 
recognition. IL-10, a cytokine with anti-inflammatory properties, has a central role in 
infection by limiting the immune response to pathogens and by thus preventing damage 
to the host. 
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Additionally, It was observed that the Agrococcus jenensis strain BA22, Arthrobacter 
oxidans strain BA30 and Micromonospora coxensis strain BA164 were active only when 
crude extracts were obtained from solid cultures, while crude extracts from the 
Arthrobacter oxydans strain BA34, either from liquid or solid culture, showed an effect on 
the cytokine release by PBMC. Moreover, Lapillicoccus sp. CO53, Saccharopolyspora 
shandongensis strain CO86 and Sphingobium sp. CO132 were active only when crude 
extracts were obtained from liquid cultures. 
 
5.4. Secondary metabolites from actinomycete and sphingomonad isolates  
Isolumichrome 
Bioactivity-guided fractionation of the active and putatively novel strains Sphingobium sp. 
CO105 and Lapillicoccus sp. CO53 was conducted using chromatographic, spectrometric 
and spectroscopic techniques. Strain Sphingobium sp. CO105 was found to produce the 
isoalloxazine isolumichrome (Figure 35), which was previously isolated from the Chinese 
marine sponge Cinachyrella australiensis by Li et al. in 2004. There are no reports of 
biological activity of isolumichrome in the literature. In this study, isolumichrome showed 
protease inhibitory activity with an IC50 value of 0.20 M, when tested against the 
protease rhodesain. Isolumichrome was also active against the proteases cathepsins B 
and L as well as against falcipain-2. However, it will prove valuable to synthesize 
isolumichrome in the future, and to confirm the biological activity, as well as to produce 
new synthetic derivatives of isolumichrome in order to conduct further activity/structure 
relationship studies. In this project no new compounds were found, nevertheless it is 
recommended to establish strategies in order to isolated novel compounds from 
sphingomonad strains. An interesting approach would be to focus the search for novel 
compounds on certain groups of metabolites. For example, glycosphingolips are a group 
of compounds with immunomodulatory substances commonly produced by 
sphingomonad strains (see introduction). Directing efforts to the isolation of this kind of 
metabolites, would augment the likelihood of finding novel sphingomonad-derived 
molecules and it will also reduce the exhaustive effort of screening the whole crude 
extract.  
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Figure 35. Isolumichrome 
 
 
Compound CO105-23-11 
Strain Sphingobium sp. CO105 produced the immunomodulatory compound CO105-23-
11, which induced TNF and IL-10 cytokine production and additional ESI-MS analysis 
showed an ion peak at m/z 511 [M+H]+. Nevertheless, the elucidation of the structure of 
compound CO105-23-11 has yet to be pursued, as well as the evaluation of its 
mechanism of action, by means of performing in vitro assays with cells of the immune 
system to evaluate the responding cell types, the toxicity and apoptosis/necrosis. The 
study of the mechanism of action of bioactive compounds was not included in the major 
aims of this PhD project; it will be very interesting to perform further experiments to gain 
insight into the structure and mechanism of action of compound CO105-23-11, which 
might be a novel immunomodulatory substance. 
 
p-Aminosalicylic acid methyl ester 
Strain Lapillicoccus sp. CO53 (solid culture) was found to produce the antibiotic 
compound p-aminosalicylic acid methyl ester (Figure 36), isolated previously from the 
genus Actinoplanes and patented by Celmer et al. in 1979 (Pfizer Inc. New York). 
Interestingly, the synthetic analog p-aminosalicylic acid (PAS) is currently commercially 
available and is used in the treatment of tuberculosis and inflammatory bowel 
diseases (Daniel et al., 2004). In addition, PAS has served as starting material to 
synthesize a series of hydrophobic p-aminosalicylic acid derivatives which are active 
against the influenza A virus (Zhang et al., 2008b). 
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Figure 36. p-Aminosalicylic acid methyl ester 
 
 
Secondary metabolites isolated from Lapillicoccus sp. BA53 
Besides, the compounds benzyldiketopiperazine, SA4-3, bis(3-indolyl)-3H-
indolylidenmethan, indole-3-carbaldehyde, arphamenine A and cyclo(L-Val-L-Phe) were 
found to be produced by strain Lapillicoccus sp. CO53 (liquid culture) (Figure 37). 
Compound SA4-3 isolated from the genus Streptomyces, possess antimicrobial activity 
against Gram-positive and Gram-negative bacteria (Toshiyuki, 1987). Indole-3-
carbaldehyde has been previously isolated from the red alga Chondria sp., and in 2003 
was reported by Shimizu et al. for its tyrosinase inhibitory activity. Arphamenine A is an 
aminopeptidase B inhibitor isolated from the marine bacterial strain Chromobacterium 
violaceum by Umezawa et al. in 1983. There are no bioactivity reports of the compounds 
benzyldiketopiperazine, bis(3-indolyl)-3H-indolylidenmethan and cyclo(L-Val-L-Phe). 
Even though compounds isolated from the liquid culture of strain Lapillicoccus sp. BA53 
did not show protease inhibitory or immunomodulatory activities, it will be profitable for 
future projects to evaluate the biological activity, using different screening approaches, as 
well as to synthesize derivatives and evaluate their biological potential.  
 
Bioactivity-guided fractionation has been the most successful strategy to isolate bioactive 
secondary metabolites from marine sources (Ebada et al., 2008). The bioactivity-guided 
scheme followed to pursue this project involved a wide spectrum of biological activities, 
which served to successfully detect the most promising bacterial isolates. For future 
research, I suggest that crude extracts and fractions obtained from bacterial isolates need 
to be monitored, using high resolution mass spectrometry in order to detect known 
compounds in an early stage, and thus direct the efforts of isolation and purification only 
to novel molecules. 
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Figure 37. Secondary metabolites isolated from strain Lapillicoccus sp. BA53  
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6. Conclusions 
 
The cultivation of 79 strains belonging to 20 different Actinomycetales genera as well as 
seven strains belonging to two Sphingomonadales genera represents a considerable 
diversity of culturable bacteria in 18 Caribbean sponges. The isolation of rare 
actinomycete genera that have not previously been reported from marine organisms, as 
well as the identification of seven putatively novel actinomycete and sphingomonad 
species based on the phylogenetic analysis of their 16S rRNA gene sequence, 
interestingly adds to the microbial population associated with marine sponges. These 
results further prove that marine sponges still remain a relatively untapped resource for 
actinomycetes and sphingomonads.  
 
Moreover, anti-protease activities against cathepsin B and L, rhodesain and falcipain-2, 
as well as immunomodulatory activities, specifically the induction of cytokine release by 
PBMC and induction of cell proliferation were found to be exhibited by the crude extracts 
from marine sponges and their associated actinomycete and sphingomonad isolates. 
These results show marine sponges and their associated bacteria as potential sources for 
developing protease inhibitors and immunomodulatory substances. Bioactivity-guided 
fractionation of crude extracts prepared from marine sponges and their associated 
actinomycetes and sphingomonads yielded two protease inhibitors and one 
immunomodulatory substance. Additionally, six known compounds were identified from 
strain Lapillicoccus sp. BA53. Even though all compounds found in this study are known 
secondary metabolites, future bioinformatics approaches can be used to evaluate the 
biological potential of the metabolites here presented. The results of this study highlight 
the therapeutic potential of these secondary metabolites; therefore, studies regarding the 
structure/activity relationship of synthetic derivatives of these compounds will indeed be 
an advantageous pursuit. 
 
Finally, I would like to conclude by saying that this PhD thesis is an interdisciplinary 
project that merged biology and chemistry and highlights the potential of marine sponges 
and their associated bacteria to produce bioactive metabolites that might lead to the 
development of drug candidates against infectious and immune diseases. 
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7. Outlook 
 
Further genotypic and phenotypic characterizations of the seven putatively novel isolates 
presented in this study should be done in order to confirm the phylogenetic affiliation of 
these strains as well as to describe in more detailed their morphological and biochemical 
characteristics. Moreover, different cultivation conditions of the sponge associated 
bacteria e.g. the use of different media, temperature, etc. will increase the diversity of the 
isolates, and in consequence will conduct to a higher production of bioactive secondary 
metabolites. 
 
In order to further increase the number of novel secondary metabolites from marine 
sponges as well as from their associated actinomycetes and sphingomonads, various 
extraction methods (different resins: amberlite, RP-18, sephadex, etc) and solvents 
(acetone, ethyl acetate, methanol, etc) as well as different chromatographic techniques 
(column chromatography, semipreparative HPLC, etc) can be used, which might lead to a 
higher variety of biologically active compounds.  
 
Another valuable strategy in natural product discovery, which can be employed in future 
studies, is the more directed search of bioactive compounds taking the prior knowledge of 
the secondary metabolite capacities of an organism into account. For instance, the 
search for glycosphingolipids from sphingomonads or the search for brominated alkaloids 
from sponges of the order Verongida might represent a more direct route to the discovery 
of novel chemical compounds.  
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Annex 
 
I. Abbreviations and Acronyms  
 
H  chemical shift (ppm) 
°C  degree Celsius  
ASW  artificial seawater 
BLAST  basic local alignment search tool 
BSS/BSA Balanced salt solution/bovine serum albumin 
bp  base pair 
ca.  approximately 
CBA  cytometric bead array 
13C-NMR carbon nuclear magnetic resonance 
CB  cathepsin B 
CL  cathepsin L 
COSY  correlation spectroscopy 
DNA  deoxyribonucleic acid 
DMEM  Dulbecco's Modified Eagle Medium 
DMSO  dimethyl sulfoxide  
DTT  dithiothreitol 
EDTA  Ethylenediaminetetraacetic acid 
ELISA  enzyme-linked immunosorbent assay 
ESI  electrospray ionization  
EtOH  ethanol 
FBS  fetal bovine serum 
Fp-2  falcipain-2 
g  gram 
h  hour 
H2Od  distilled water 
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H2Odd  double distilled water 
1H-NMR  proton nuclear magnetic resonance 
HMA  high microbial abundance 
HPLC  high performance liquid chromatography 
Hz  hertz 
IL  interleukin 
IFN-   interferon-gamma   
ISP  International Streptomyces Project 
kb  kilobase 
L  liter 
LC  Liquid chromatography 
LMA  low microbial abundance 
M  molar  
MeCN  acetonitrile  
MeOD  deuterated methanol 
MeOH  methanol 
MSD  mass selective detector 
mg  milligram 
MHz  megahertz 
min  minute 
mL  milliliter 
mM  millimolar 
MS  mass spectrometry 
MR  microplate reader 
NMR  nuclear magnetic resonance 
OD  optical density 
ORF  open reading frame 
PBMC  peripheral blood mononuclear cells 
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PCR  polymerase chain reaction 
ppm  parts per million 
Q-TOF  Quadrupole time-of-flight mass spectrometer 
RFLP  restriction fragment length polymorphism 
Rho  rhodesain  
rRNA  ribosomal RNA  
RNA  ribonucleic acid 
RP  reverse phase  
RPMI  Roswell Park Memorial Institute 
rpm  revolutions per minute 
Rt  retention time 
RT  room temperature 
sp.   species 
Tbb  Trypanosoma brucei brucei 
TFA  trifluoroacetic acid 
TNF  tumor necrosis factor 
U  enzyme units 
g  microgram 
l  microliter 
M  micromolar 
UPLC  Ultra performance liquid chromatography 
v/v   volume concentration 
w/v  weight per volume   
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II. Buffers, Solutions and Media 
The following buffers, solutions and media were sterilized by autoclaving at 121 C for 30 
min. Antibiotics and other solutions, when specified, are added to the media at hand-
warm temperature following sterilization. Media containing agar were aseptically poured 
into sterile disposable Petri dishes and allowed to solidify at room temperature. 
 
Buffers and Solutions 
 
Artificial seawater 
NaCl 234.70 g 
Na2SO4 39.20 g 
MgCl2.6H2O 106.40 g 
CaCl2 11.00 g 
NaHCO3 1.92 g 
KCl 6.64 g 
SrCl2 0.024 g 
KBr 0.96 g 
H3BO3 0.24 g 
NaF 0.03 g 
H2Odd ad 10.00 L 
 
EDTA (ethylenediamine tetraacetic acid) (0.5 M, pH 8.0) 
Na2EDTA.2H2O 93.05 g 
NaOH (10 M) ca. 25.00 mL 
H2Odd ad 500 mL 
 
The pH of the solution was adjusted to 8.0 with NaOH since EDTA does not begin to 
dissolve until the pH reaches 7.0. Water was added to make a final volume of 500 mL. 
 
Gel-loading buffer (5x) 
Bromphenol blue  25.0 mg 
Xylene cyanol 25.0 mg 
Ficoll (type 400) 1.5 g 
H2Odd ad 10.0 mL 
 
IPTG (Isopropyl- -D-thiogalactopyranoside) (1 M) 
IPTG 2.38 g 
H2Odd ad  10.00 mL 
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Plasmid mini-prep buffers 
 
Buffer P1  
Tris-Cl (1 M, pH 7.5) 5.0 mL 
EDTA (0.5 M, pH 8.0) 2.0 mL 
RNAse A (10 mg/mL) 1.0 mL 
H2Odd ad  
  
100.0 mL 
Buffer P2  
NaOH (2 M)  5.0 mL 
SDS (10%)  10.0 mL 
H2Odd ad 
   
100.0 mL
  
Buffer P3  
Potassium acetate  29.4 g 
Acetic acid ca.  11.5 mL 
H2Odd  ad  100.0 mL 
 
The pH of the solution was adjusted to pH to 5.5 using glacial acetic acid, and water was 
added to make a final volume of 100 mL. 
 
SDS (sodium dodecyl sulfate) solution (10% w/v) 
SDS   10.0 g 
H2Odd ad  100.0 mL 
 
SDS was first dissolved in 80 mL water, and was heated to 50 C to accelerate 
dissolution. The pH of the solution was adjusted to 7.0 by adding several drops of 
concentrated HCl, and water was added to make a final volume of 100 mL. 
 
TAE buffer (5x) 
 
Tris base  242.00 g 
Sodium acetate.3H2O 136.12 g 
Na2EDTA.2H2O  19.00 g 
H2Odd ad 1.00 L 
 
The above reagents were dissolved in 700 mL water and the pH was adjusted to 7.2 with 
acetic acid. Water was added to make a final volume of 1 L.  
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X-gal (5-bromo-4-chloro-3-indolyl- -D-galactoside) (5% w/v) 
X-gal   0.5 g  
DMFA ad  10.0 mL  
       
Media    
ISP 2    
Yeast extract  4.0 g  
Malt extract  10.0 g  
Glucos   4.0 g  
Agar   18.0 g  
H2Odd ad  1.0 L  
   
LB (Luria-Bertani) agar   
Peptone   10.0 g  
Yeast extract  5.0 g  
NaCl   5.0 g  
Agar   18.0 g  
H2Odd ad  1.0 L  
 
LB/amp 
  
LB agar   1.0 L  
Ampicillin   1.0 mL  
Filter-sterilized ampicillin (100 g/mL) was added to LB agar after autoclaving. 
 
LB/amp/IPTG/X-gal 
 
LB agar   1.0 L  
Ampicillin (100 mg/mL) 1.0 mL  
IPTG (1 M)  0.4 mL  
X-gal (5%) 
   
1.6 mL  
Filter-sterilized ampicillin (100 g/mL), IPTG (0.5 mM) and X-gal (80 g/mL) were added to LB 
agar after autoclaving. 
 
M1 
  
Soluble starch  10.0 g  
Yeast extract  4.0 g  
Peptone   2.0 g  
Agar   18.0 g  
Artificial seawater a  1.0 L  
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M2   
Glycerin (100%)  6.0 mL  
Arginine   1.0 g  
K2HPO4   1.0 g  
MgSO4   0.5 g  
Agar   18.0 g  
Artificial seawater a  1.0 L  
   
M7   
Peptone   2.0 g  
Asparagine           0.1 g  
Sodium propionate  4.0 g  
K2HPO4   1.0 g  
MgSO4   0.1 g          
FeSO4   0.001 g  
Glycerol   5.0 g  
NaCl   20.0 g  
Agar   18.0 g  
Artificial seawater ad 1.0 L  
   
NaSt21Cx   
Solution A   
  K2HPO4   1.0 g  
  Agar   18.0 g  
  Artificial seawater          750.0 mL  
Solution B   
  KNO3   1.0 g  
  MgSO4    1.0 g  
  CaCl2.2H2O  1.0 g  
  FeCl3   0.2 g  
  MnSO4.7H2O  0.1 g  
 Artificial seawater  250.0 mL  
Solutions A and B were autoclaved separately and subsequently combined.  
 
Oligotropic 
 
Tryptone  0.50 g 
C3H7Na2O6P  0.1 g 
Yeast extract  0.05 g 
Agar   12 g 
H2Od ad  1.0 L 
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SOC medium  
Tryptone  20.0 g 
Yeast extract  5.0 g 
NaCl (1 M)  10.0 mL 
KCl (1 M)  2.5 mL 
MgCl2 (1 M)  10.0 mL 
MgSO4 (1 M)  10.0 mL 
Glucose (2 M)  10.0 mL 
H2Od ad  1.0 L 
 
Tryptone (2%), yeast extract (0.5%), NaCl (10 mM) and KCl (10 mM) were added to 970 
mL distilled water prior to autoclaving. The following filter-sterilized solutions: MgCl2 (10 
mM), MgSO4 (10 mM) and glucose (20 mM) were subsequently added to the medium 
after autoclaving. 
   
YPD medium  
Yeast extract  10.0 g 
Peptone  20.0 g 
Glucose  20.0 g 
H2Odd ad  1.0 L 
 
Zobell medium 
 
Yeast extract  1.0 g 
Peptone  5.0 g 
Artificial seawater 750.0 mL 
H2Odd ad  1.0 L 
 
 
III. Cells  
Cell type Source 
Human PBMC Institute of Transfusion Medicine and 
Hemotherapy, University Clinic Würzburg  
J774.1 murine macrophages Institute for Molecular Infection Biology, 
University of Würzburg  
Human kidney epithelial 293T cells Institute for Molecular Infection Biology, 
University of Würzburg.  
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IV. Chemicals  
Chemical name Manufacturer 
AB-positive human serum PAA Laboratories GmbH 
Acetic acid AppliChem 
Acetonitrile Sigma 
Agar, granulated Difco 
Agarose, ultrapure Gibco 
Ampicillin  AppliChem 
Arginine Sigma 
Asparagine Sigma 
Boric acid (H3BO3) AppliChem 
5-bromo-4-chloro-3-indolyl- -D-galactoside (X-Gal) Sigma 
Bromphenol blue Merck 
Calcium chloride (CaCl2) AppliChem 
Cbz-Phe-Arg-AMC Bachem 
Chloroform Roth 
Cycloheximide Sigma 
Dipotassium hydrogen phosphate (K2HPO4) Roth 
Dimethylformamide AppliChem 
Dimethylsulfoxide Sigma 
Ethanol absolute (EtOH) Merck 
Ethanol denatured (EtOH) Roth 
Ethidium bromide (1% solution)  Roth 
Ethyl acetate Roth 
Ethylenediamine tetraacetic acid dihydrate  Serva 
Ferric chloride (FeCl3) Roth 
Ferrous sulfate heptahydrate (FeSO4 .7H2O) Fluka 
Gentamicin Sigma 
Glucose  AppliChem 
Glutaraldehyde Sigma 
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Chemical name Manufacturer 
Glycerin/Glycerol  Roth 
Hepes AppliChem GmbH 
Hydrochloric acid (HCl) AppliChem 
H2N-Abz-Ser-Val-Thr-Leu-Gln-Ser-Gly-(NO2)Tyr-
Arg-(MTS)-TFA-salt 
Radim Vicik, Würzburg, now in 
Switzerland 
Isopropanol  Roth 
Isopropyl- -D-1-thiogalactopyranoside (IPTG) Sigma 
Lymphocyte separation medium PAA Laboratories GmbH 
Malt extract AppliChem 
Magnesium chloride hexahydrate (MgCl2.6H2O) AppliChem 
Magnesium sulfate heptahydrate (MgSO4.7H2O) AppliChem 
Manganese chloride tetrahydrate (MnCl2. 4H2O) AppliChem 
Manganese sulfate (MnSO4.7H2O) Roth 
Methanol Sigma, Roth 
Nalidixic acid Sigma 
Nystatin Sigma 
Oxacillin Sigma 
Penicillin Sigma 
Peptone Roth 
Phenol  AppliChem 
Potassium acetate (CH3CO2K) Applichem 
Potassium bromide (KBr) AppliChem 
Potassium chloride (KCl) Fluka 
Potassium nitrate (KNO3) AppliChem 
Propylene oxide Roth 
Rifampin Sigma 
Saccharose Roth 
Sodium acetate trihydrate  AppliChem 
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Chemical name Manufacturer 
Sodium bicarbonate (NaHCO3) Merck 
Sodium chloride (NaCl) Roth 
Sodium dodecyl sulfate (SDS) AppliChem 
Sodium fluoride (NaF) Fluka 
Sodium glycerolphosphate (C3H7NaO6P) Roth 
Sodium hydroxide (NaOH) AppliChem 
Sodium propionate (C3H5NaO2) AppliChem 
Sodium sulfate (Na2SO4) Merck 
Sodium thiosulfate (Na2S2O3) AppliChem 
Starch Roth 
Streptomycin Sigma 
Strontium chloride (SrCl2) Fluka 
RPMI   Grünenthal GmbH  
Tetracycline Sigma 
Trifluoroacetic acid (TFA) Sigma 
Tris (hydroxymethyl) aminomethane hydrochloride  Sigma 
[3H]-thymidine Hartmann Analytic 
Tryptone Roth 
Tyrosine Sigma 
Vancomycin Sigma 
Xylene cyanol AppliChem 
XAD-16 resine Sigma 
Yeast extract Gibco 
Z-Arg-Leu-Arg-Gly-Gly-AMC-acetate salt Bachem 
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V. Computer Programs 
Software Application Reference 
Align sequence alignment and 
editing 
Hepperle 2002 
AntiMarin database marine natural products 
database 
University of Canterbury, New Zealand 
 
ARB phylogenetic tree construction http://www.arb-home.de/ 
BLAST sequence 
comparison/alignment  
http://www.ncbi.nlm.nih.gov/BLAST/ 
ChemBioOffice 2008 illustration of chemical 
structures 
Chem Office 2004 
ClustalX alignment of nucleotide and 
amino acid sequences 
http://www-igbmc.u- strasbg.fr/ BioInfo 
/ClustalX/Top.htmL 
Dictionary of Natural 
Products 
online database of natural 
products 
http://www.chemnetbase.com 
FCAP Array software flow cytometry data analysis 
and processing 
Soft Flow, Inc., USA 
MestReNova NMR processing, analysis and 
reporting 
http//mestrelab.com 
Multi Analyst 1.1 documentation of agarose gel BioRad 
Phylip phylogenetic tree construction http://evolution.genetics.washington.ed
u /phylip/getme.htmL 
SciFinder Scholar natural products access tool  http://www.cas.org/scifinder/scholar 
Treeview visualization of phylogenetic 
trees 
http://taxonomy.zoology.gla.ac.uk/rod 
/treeview.htmL 
Vector NTI Advance 
TM 10 
ORF identification and 
sequence annotation 
https://catalog.invitrogen.com/index.cf
m?fuseaction=userGroup.downloadCe
nter 
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VI. Enzymes and Kits 
Name of Enzyme/ Kit Manufacturer 
pGEM-Teasy vector system   Promega 
Cathepsin L (Paramecium tetraurelia) Calbiochem 
Cathepsin B (human liver)   Calbiochem 
Falcipain 2 (Plasmodium falciparum) Prof. P. Rosenthal, SF, USA/Prof. C. Kisker, 
Germany 
Rhodesain (Trypanosoma rhodesiense) Prof. J. McKerrow, Dr. C. Caffrey, SF, USA/ 
Prof. C. Kisker, Germany 
Human Soluble Protein Flex Sets BD Biosciences, San Jose, CA, USA 
Human Soluble Protein Master Buffer  BD Biosciences, San Jose, CA, USA 
QIAquick PCR purification kit  Qiagen 
Restriction endonucleases and buffers New England Biolabs  
RNase  Roche 
SARS-CoV Mpro and SARS-CoV Plpro Prof. J. Ziebuhr, Germany/Prof. C. Kisker, 
Germany 
Taq DNA polymerase and buffer Qiagen 
T4 DNA ligase and buffer New England Biolabs 
GeneRulerTM 1kb DNA ladder Fermentas 
GeneRulerTM 100bp DNA ladder Fermentas 
 
 
VII. Equipment and Supplies 
Equipment/ Supplies Manufacturer Specifications 
Autoclave Fedegari 
H+P Labortechnik 
Tec 120, 9191E, FV 3.3 
Varioklav 500, 135S  
Benchtop centrifuge Hereaus Instruments Biofuge Frasco 
Distilling apparatus for H2Odd GFL Bi-Dest 2304 
Disposable cuvette Plastibrand halbmikro 1,5 mL 
Electroporator EquiBio Easyject PRIMA 
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Equipment/ Supplies Manufacturer Specifications 
Electroporation cuvette EquiBio EPC 102 
ELISA plate reader Cary Eclipse fluorescence 
spectrophotometer 
Varian 
  
Filter disks Becton Dickinson - 
Filter membranes Millipore Millex-GS 0.22 m 
Flow cytometer BD Biosciences LSR II 
Gel documentation BioRad Gel Doc 2000 
Gel electrophoresis chamber BioRad - 
Heat block Laboratory Devices Digi-Block Jr. 
HPLC Agilent Agilent 1100 
 Agilent  ProStar 
HPLC columns Phenomenex RP18 
 Varian  RP18 
Ice maker Scotsman AF-20 
Incubator Heraeus 
Memmert 
Kelvitron®t 
TV 40b  
LC-MS Agilent 1100 LC/MSD trap 
MS Synapt G2 HDMS  TOF-MS 
MS Bruker Daltonics micrOTOF 
Liquid scintillation counter PerkinElmer  
Magnetic stirrer Labinco L32 
Micropipettes 
 
Microlab 
Microlab 
Microlab 
Microlab 
MicroOne 0,5-10 L 
MicroOne 2-20 L 
MicroOne 20-200 L 
MicroOne 100-1000 L 
 
Microfuge tubes  Sarstedt 1,5 mL; 2,0 mL 
  Abgene 
Abgene 
0,5 mL Thermo tubes 
0,2 mL Thermo Stripes  
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Equipment/ Supplies Manufacturer Specifications 
Microplates Nalgene NunclonTM 
Microwave AEG 
Privileg 
Micromat 
8020 
NMR Bruker 
Bruker 
Bruker DMX 600  
Advance 400 MHz 
PCR cycler Biometra T3-Thermocycler 
Petri dishes, round Greiner - 
Petri dishes, square Nalgene NunclonTM 
96 well plates Greiner Bio-one Cell culture 
14 well plates Greiner Bio-one Cell culture 
pH Meter  WTW MultiLine P4, SenTix 41 
Pin replicator Nalgen Nunc International 384 pin replicator 
Quartz cuvette Hellma Suprasil 
Refrigerator Privileg Superöko 
Rotary evaporator Heidolph Laborota 4010 
Sequencer ABI Prism ABI 377XL 
Spectrophotometer Pharmacia Biotech 
PeqLab 
Ultraspec 3000 
NanoDrop ND1000 
Shakers Braun 
Edmund Bühler 
Eppendorf 
Infors 
Certomat U 
SM-30 
Rotationsmischer 3300 
HT 
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VIII. Microorganisms 
Microorganism Application 
Staphylococcus aureus NCTC 8325 Bioactivity testing 
Staphylococcus epidermidis RP62A Bioactivity testing 
Enterococcus faecalis JH212 Bioactivity testing 
Enterococcus faecium 6413 Bioactivity testing 
Escherichia coli 536  Cloning 
Escherichia coli XL1-Blue Bioactivity testing 
Escherichia coli EPI100 Cloning 
Pseudomonas aeruginosa  Bioactivity testing 
Yersinia pseudotuberculosis 252 01A Bioactivity testing 
Yersinia pestis KUMA Bioactivity testing 
Candida albicans 5314 (ATCC 90028) Bioactivity testing 
Trypanosoma brucei brucei 221  Bioactivity testing 
Leishmania major Bioactivity testing 
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 IX. Oligonucleotides 
Oligonucleotide Sequence 5’ – 3’ Annealing ( C) Reference Specificity 
27f 
1492r 
GAGTTTGATCCTGGCTCA 
TACGGCTACCTTGTTACGACTT 
56 Lane 1991 bacterial 16S rRNA gene (universal) 
56 Lane 1991 bacterial 16S rRNA gene (universal) 
341f 
907r 
CCTACGGGAGGCAGCAG 
CCGTCAATTCMTTTGAGTTT 
59 Muyzer 1993 bacterial 16S rRNA gene (universal) 
52 Muyzer 1993 bacterial 16S rRNA gene (universal) 
SP6 
T7 
ATTTAGGTGACACTATAG 
GTAATACGACTCACTATAGGG 
45 Promega pGEM-T easy cloning vector 
45 Promega pGEM-T easy cloning vector 
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Supplementary Material  
 
Figure S1. RP LC-MS profile of amphitoxin  
 
Figure S2. ESI-MS spectrum for amphitoxin  
 
Figure S3. 1H-NMR spectrum for amphitoxin in CD3OD (400 MHz) 
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Figure S4. RP LC-MS profile of miraziridine A 
 
Figure S5. ESI-MS for miraziridine A 
 
Figure S6. Chromatograms of fractions obtained from the crude extract from liquid 
culture of strain BA53 
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Figure S7. Fragment analysis of compounds identified in the fractions obtained from 
crude extracts from the liquid culture of strain BA53. 
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Figure S8. Chromatographic profile for isolumichrome (detection at 254 nm) 
 
Figure S9. ESI-MS spectrum for isolumichrome.  
 
 
Figure S10. 1H-NMR spectrum for isolumichrome in CD3OD (600 MHz) 
 
Isolumichrome 
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Figure S11. COSY spectrum of isolumichrome in CD3OD (600 MHz) 
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